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Abstract
Background: Rheumatoid arthritis (RA) is associated with a substantially increased risk for 
cardiovascular (CV) morbidity and mortality. Th is cannot be fully explained by traditional CV 
risk factors, but a key driver behind the excess risk is systemic infl ammation. Along with their 
CV burden, RA patients are at increased risk for other comorbidities such as hypothyroidism and 
depressive symptoms. Th e aim of this study was to evaluate the prevalence of CV comorbidities, 
CV risk factors, and hypothyroidism among RA patients in comparison to those of the general 
population at the time of RA diagnosis. We also aimed to determine, among patients with early 
RA, the contribution of psychiatric and CV comorbidities as causes of long-term work disability 
(WD). Lastly, we assessed CV mortality rates in early RA and the impact of RA medications on 
CV mortality.
Methods: Between 2000 and 2007, all patients diagnosed with RA in Finland were possible to 
identify from a Finnish nationwide register on special reimbursements for medicine expenses. 
Th e same register provided information on the presence of comorbidities antedating RA 
diagnosis. From the pension registers, we identifi ed those RA patients who were, by the end of 
2008, granted permanent or temporary disability pensions. Th e incidences of disability pensions 
were assessed as those with CV diseases or psychiatric disorders as their main causes. Causes of 
death were obtainable until the end of 2008. A multivariable competing-risks model served to 
assess the impact of variables such as RA medications on CV mortality. We compared the main 
outcomes, that is, the prevalence of comorbidities at RA diagnosis, the incidence of comorbidity-
related disability pensions, and CV mortality rates to those of the age- and sex-specifi c Finnish 
population, and calculated standardized rate, incidence and mortality ratios (SRRs, SIRs, and 
SMRs). 
Results: In a population of 7,209 RA patients, the risk of having coronary heart disease (CHD) at 
RA diagnosis was slightly elevated, the SRR being 1.10 (95% confi dence interval [CI] 1.01–1.20). 
Higher SRRs for CHD seemed to relate to younger age at RA onset. Th e SRR for levothyroxine-
treated hypothyroidism at RA diagnosis was 1.51 (95% CI 1.35 to 1.67). SRR was highest, almost 
2.5, among women with RA aged 20 to 49, the excess prevalence of hypothyroidism decreasing 
steadily and fading in older age groups. From 2000 to 2008, of 7,831 RA patients, 1,095 (14.0%) 
were granted a disability pension. Aft er adjusting for competing risks, the 9-year cumulative 
incidence of WD resulting from RA was 11.9%, from a psychiatric comorbidity 1.3%, and from 
a CV disease 0.5%. SIR of WD resulting from CV disease was 1.75 (95% CI 1.23 to 2.51) and 
SIR of WD resulting from psychiatric disorders was 0.99 (95% CI 0.80 to 1.23). By the end of 
2008, of 14,878 RA patients, 1,157 had died, 501 (43%) from CV causes. Th e SMR in the entire 
RA cohort was 0.57 (95% CI 0.52–0.62). Th e RF-positive men had the highest SMR (0.70, 95% 
CI 0.60–0.83), whereas the RF-negative women had the lowest SMR (0.43, 95% CI 0.35–0.53). 
Glucocorticoids were, along with the presence of CV comorbidities, diabetes, and RF, associated 
with increased CV mortality, whereas methotrexate was associated with decreased CV mortality. 
Conclusions: Th e risks for CHD and hypothyroidism were already higher among RA patients 
at RA diagnosis. Psychiatric and CV comorbidities were the primary causes of long-term WD 
much less frequently than was RA itself; the risk for WD due to CV disease, however, was higher 
in RA than in the general population. During the era of modern treatment regimens for RA, 
the risk of CV death during the early years of RA was not elevated. Th ese fi ndings highlight the 
importance of alertness for comorbid conditions and their optimized care in RA, already in the 
early years of the disease.
Tiivistelmä
Tausta ja tavoitteet: Nivelreumaan liittyy lisääntynyt sydän- ja verisuonitautisairastavuus 
ja -kuolleisuus. Tämä ei selity pelkästään perinteisillä sydänsairauksien riskitekijöillä, vaan 
nivelreumaan liittyvä systeeminen tulehdusreaktio lisää voimakkaasti sydäntapahtumien 
riskiä. Nivelreumapotilaat kärsivät muistakin liitännäissairauksista, kuten kilpirauhasen 
vajaatoiminnasta ja masennuksesta enemmän kuin muu väestö keskimäärin. Tavoitteenamme 
oli tutkia sydän- ja verisuonitautien ja kilpirauhasen vajaatoiminnan esiintyvyyttä 
nivelreumapotilailla taudin diagnoosihetkellä. Pyrimme myös selvittämään, kuinka 
yleisiä sydän- ja verisuonisairaudet ja psykiatriset sairaudet ovat nivelreumapotilaiden 
pitkäaikaistyökyvyttömyyden aiheuttajina. Lisäksi tutkimme nivelreumapotilaiden sydän- ja 
verisuonitautikuolleisuutta ensimmäisinä sairastamisvuosina ja nivelreuman lääkehoidon 
vaikutusta sydän- ja verisuonitautikuolleisuuteen. 
Menetelmät: Tunnistimme Kelan erityiskorvattavuusrekisteristä kaikki Suomessa vuosina 2000-
2007 diagnosoidut nivelreumapotilaat ja heillä todetut liitännäissairaudet. Diagnoosihetkellä 
työkykyisten potilaiden sydän- ja verisuonitautien ja psykiatristen sairauksien takia myöhemmin 
myönnettyjen työkyvyttömyyseläkkeiden ja kuntoutustukien ilmaantuvuus tunnistettiin 
Eläketurvakeskuksen eläkerekistereistä. Sydän- ja verisuonitautikuolemien ilmaantuvuus 
analysoitiin vuoden 2008 loppuun asti. Erilaisten tekijöiden, kuten nivelreuman lääkehoidon 
vaikutusta sydän- ja verisuonitautikuolleisuuteen arvioitiin kilpailevien kuolemansyiden 
regressiomallilla. Tärkeimpien päätetapahtumien yleisyyttä nivelreumakohortissa verrattiin 
Suomen väestön vastaaviin lukuihin. 
Tulokset: Sepelvaltimotauti oli 7209 potilaan nivelreumakohortissa 10 % yleisempi kuin 
vertailuväestössä jo taudin diagnoosihetkellä. Alhaisempi nivelreuman puhkeamisikä näytti 
liittyvän korkeampaan sepelvaltimotaudin riskisuhteeseen. Kilpirauhasen vajaatoiminta oli 50 % 
yleisempää nivelreuman diagnoosihetkellä kuin vertailuväestössä, suhteellisen riskin ollessa lähes 
2,5-kertainen 20-49-vuotiaiden naispotilaiden ikäryhmässä. Diagnoosihetkellä työkykyisestä 
7831 potilaasta työkyvyttömyyseläkkeelle jäi vuosina 2000-2008 1095 potilasta. Yhdeksän 
vuoden seurannassa nivelreuman aiheuttamien työkyvyttömyyseläkkeiden kumulatiivinen 
ilmaantuvuus oli 12 %, kun taas psykiatristen sairauksien ja sydän- ja verisuonitautien kohdalla 
vastaavat luvut olivat pienemmät, 1,3 % ja 0,5 %. Sydän- ja verisuonitautien aiheuttaman 
työkyvyttömyyden ilmaantuvuus oli nivelreumapotilailla 75 % korkeampi kuin väestössä 
keskimäärin, mutta psykiatristen syiden aiheuttaman työkyvyttömyyden ilmaantuvuudessa ei 
ollut eroa. Vuoden 2008 loppuun mennessä 14878 potilaan kohortista kuoli 1157 potilasta. Heistä 
501 (43 %) potilaalla oli peruskuolemansyynä sydän- ja verisuonitaudit. Nivelreumapotilaiden 
sydän- ja verisuonitautikuolleisuus ei ollut korkeampi kuin vertailuväestössä. Suurin 
suhteellinen sydän- ja verisuonitautikuoleman riski oli reumatekijäpositiivisilla miehillä ja 
pienin reumatekijänegatiivisilla naisilla. Glukokortikoidien käyttö liittyi lisääntyneeseen sydän- 
ja verisuonitautikuoleman riskiin, kun taas metotreksaatin käyttö liittyi pienentyneeseen riskiin. 
Johtopäätökset: Sepelvaltimotaudin ja kilpirauhasen vajaatoiminnan riski oli nivelreumapotilailla 
lisääntynyt jo taudin diagnoosihetkellä. Psykiatriset sairaudet ja sydän- ja verisuonitaudit olivat 
nivelreumapotilaiden pitkäaikaistyökyvyttömyyden syinä huomattavasti harvinaisempia kuin itse 
nivelreuma. Silti sydän- ja verisuonisairauksien aiheuttaman pitkäaikaistyökyvyttömyyden riski 
oli korkeampi nivelreumassa kuin väestössä keskimäärin. Sydän- ja verisuonitautikuolleisuus sen 
sijaan ei ollut koholla ensimmäisinä nivelreuman toteamista seuraavina vuosina. Havaintomme 
korostavat huolellisen liitännäissairauksien kartoituksen ja hoidon tärkeyttä jo nivelreuman 
alkuvaiheista lähtien. 
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1Rheumatoid arthritis (RA), a chronic 
infl ammatory autoimmune disease primarily 
aff ecting the joints, is associated with a 
plethora of comorbidities, especially of 
cardiovascular (CV) origin. RA patients 
suff er excessively from coronary heart 
disease (CHD), congestive heart failure 
(CHF) and stroke, and compared to the 
general population’s, their CV mortality is 
50% higher.1 Th e increased CV risk cannot 
be fully explained by traditional CV risk 
factors, even though some of these occur in 
RA more frequently than one would expect. 
Accumulating evidence points to a key 
mechanism accelerating atherosclerosis in 
RA; that is, systemic infl ammation, perhaps 
elevating CV risk even in the early phases of 
the disease. Th e important question of how 
early in the course of RA the excess CV risk 
emerges, however, remains unanswered.
Along with CV burden, RA patients 
experience increased risk for other 
comorbidities like autoimmune diseases and 
psychiatric disorders. Depressive symptoms 
are 2 to 3 times as common in RA as in 
the general population.2,3 Another disease 
that clusters with RA more frequently than 
expected is chronic autoimmune thyroiditis, 
commonly causing hypothyroidism.4,5 
Hypothyroidism itself may also be excessively 
prevalent in established RA.6 Again, to our 
knowledge, no study has yet confi rmed 
whether this association already exists in 
early phases of RA. 
Comorbidities have profound eff ects on 
many important outcomes of RA including 
disability, quality of life, and mortality.7,8 
Regarding the high rates of work disability 
(WD) related to RA, initial data suggest that 
comorbidities may further elevate the risk for 
WD.9 Existing studies on this topic, however, 
are small in size and mostly concern only 
psychiatric comorbidities,10-12 thus leaving 
considerable gaps in current knowledge. 
A great number of studies spanning 
half a century demonstrate that patients with 
established RA are at increased risk of CV 
death.13 Knowing that treatment of RA has 
improved notably during the past two decades 
and that a similar improvement has occurred 
in RA patients’ health status,14 the question 
arises whether the CV survival of RA patients 
has truly improved. Results of many mortality 
studies may not be reliably generalizable to 
RA patients alive during the era of modern 
RA treatments. 
From this background, we focused 
on elucidating selected epidemiological 
aspects of early RA, including risk for CV 
disease and hypothyroidism, contribution of 
comorbidities to WD, and CV mortality.
Introduction
INTRODUCTION
21  Rheumatoid arthritis
1.1  Overview
RA is a systemic, chronic progressive 
infl ammatory disease that is characterized by 
persistent synovitis in the small and medium-
sized joints, systemic infl ammation, and, 
in the majority of patients, autoantibodies 
to rheumatoid factor (RF) or citrullinated 
proteins or to both. RA typically aff ects the 
small joints of the hands and feet, ankles, 
knees, wrists, elbows, shoulders, and upper 
cervical spine.15 Joint pain, swelling, and 
morning stiff ness are common symptoms 
among patients with RA. Th e disease usually 
begins insidiously, and the severity of the 
symptoms oft en fl uctuates over time. Along 
with joint symptoms, various extra-articular 
manifestations and comorbidities modify 
RA’s clinical phenotype. Systemic expression 
of RA may include fatigue, fever, and anemia. 
Without eff ective treatment, ongoing joint 
infl ammation leads to destruction of cartilage 
and of articular bone, limited motility, 
deformity, chronic pain, disability, and 
decreased quality of life.
1.2  Etiology 
Genetic factors account for approximately 
50% of the risk for developing RA. Many 
susceptibility polymorphisms in more than 
30 genetic regions both inside and outside 
the human leukocyte antigen (HLA) region 
associate with RA. None of the single risk 
alleles is suffi  cient to cause RA, since their 
eff ects at the individual level are only modest 
or minor. Some risk loci are linked to 
susceptibility to other autoimmune diseases, 
and some to infl ammatory pathways.16 For 
example, the shared epitope-containing 
HLA-DRB1 alleles are strongly associated 
with the production of anti-citrullinated 
protein antibodies (ACPAs),16 and the 
PTPN22 gene locus residing outside of the 
HLA complex is a strong risk factor for many 
autoimmune diseases.17 Epigenetic factors 
also play a role in RA development.18
As to environmental risk factors, 
smoking is undoubtedly the most important 
– it doubles the risk for ACPA-positive RA,16 
a risk that may increase up to 21-fold when 
double copies of the HLA-DRB1 shared 
epitope are present.19 Moreover, one risk 
factor for RA is porphyromonas gingivalis 
infection.20 Epstein-Barr virus infection 
may be associated with RA, a possible 
mechanism for this association’s being 
molecular mimicry.21 Limited evidence exists 
that other environmental risk factors such as 
vitamin D defi ciency, high birthweight, and 
low socioeconomic status elevate the risk 
for RA.22 Interestingly, initial data suggest 
that consumption of alcohol may be dose-
dependently associated with reduced RA 
risk.23 Oral contraceptives may also reduce its 
risk.22
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31.3  Pathophysiology 
RA is characterized not only by local 
infl ammation damaging small and 
medium-sized joints but also by systemic 
infl ammation. Diff erent autoimmune and 
infl ammatory processes are variably active in 
RA, making the entire disease entity clinically 
and pathobiologically heterogeneous.16 
Th e common denominators of diff ering 
RA subsets, such as autoimmunity and 
infl ammation, are of key interest. 
1.3.1  Autoimmunity
To date, what remains to be fully elucidated is 
when and where autoimmunity in RA emerges. 
It may occur at mucosal sites including 
the lung, gastrointestinal tract, and oral 
cavity, but as RA progresses, autoimmunity 
primarily targets joints.24 Th e production 
of two known groups of autoantibodies, 
RF and ACPAs, is characteristic of RA. 
Approximately 50 to 80% of all RA patients 
have RF, ACPA, or both, and RF and ACPA 
overlap in individuals frequently.16 Th ey 
both target common autoantigens expressed 
not only inside but also outside the joints.21 
RF, the classic autoantibody in RA, is an 
IgM, IgA, or IgG antibody against the Fc 
fragment of the IgG antibody.16 ACPAs are a 
group of autoantibodies against citrullinated 
proteins, that is, proteins in which arginine 
residues are post-translationally modifi ed 
into citrulline by peptidylarginine deiminase 
enzymes.25 Citrullinated proteins recognized 
by ACPAs include extracellular proteins such 
as fi laggrin, type II collagen, fi brinogen, and 
fi bronectin, as well as cytoplasmic and nuclear 
proteins such as vimentin and histones.26 
ACPAs were discovered later than was 
RF, but are becoming increasingly important 
for several reasons. Firstly, they are more 
sensitive and specifi c for the diagnosis of 
RA than is RF, and they are better predictors 
of poor prognosis.27 Secondly, they are a 
cornerstone autoantibody pathogenetically – 
one of the key mechanisms in the induction 
of synovitis may be loss of tolerance to 
citrullinated proteins.21 Of note, citrullination 
reactions are expedited both by smoking and 
by porphyromonas gingivalis infections,21 
thus providing a mechanism by which these 
environmental risk factors can magnify 
the risk for ACPA-positive RA. Although 
citrullinated proteins occur not only in the 
synovia but also in other organs, an immune 
response against them somehow arises only 
locally in the synovia.21
Within the joint soon to become 
infl amed, citrullinated proteins and other 
possible autoantigens activate cluster of 
diff erentiation 4 (CD 4) helper T cells, 
mostly of Th 1 and Th 17 subsets.15 Th e 
activated helper T cells produce cytokines 
and activate an army of other cells of the 
immune system to attack the self-antigens.15 
Synovium may be able to act as a secondary 
lymphoid organ and to serve as a platform 
for the stimulation of T and B cells.21 
Adaptative immunity—the action of B and 
T lymphocytes—is pivotal, especially during 
the preclinical and early phases of RA, but is 
also involved in perpetuation of the disease.21 
In the later phases of RA, innate immunity 
eff ector cells, especially macrophages, usually 
predominate.21
RA pathogenesis is a slow process—
the sera of RA patients already show both 
RF and ACPAs more than ten years before 
clinical RA onset.28 Despite this, in a minority 
of seronegative patients, seroconversion to 
seropositive disease occurs aft er RA’s clinical 
eruption.29
1.3.2  Inflammation and joint 
destruction
Th e local autoimmune response in the 
synovium leads to homing of leukocytes 
as well as to infl ammatory cascades and 
amplifi cation loops. In addition to B and T 
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fi broblast- and macrophage-like synoviocytes 
accumulate in the synovium.15 Macrophages 
are very important eff ector cells of synovitis, 
acting via secretion of tumor necrosis factor 
α (TNF-α), interleukin 6 (IL-6), interleukin 
1 β (IL-1β), and metalloproteinases. Th ey 
also carry out phagocytosis and antigen 
presentation.21 Besides macrophages, other 
innate eff ector cells such as natural killer 
cells, neutrophils, and mast cells reside in 
rheumatoid synovial tissue.21
Leukocytes produce an armamentarium 
of cytokines forming a redundant and 
pleiotropic network of a predominantly 
proinfl ammatory nature. Important 
proinfl ammatory cytokines in RA include 
TNF-α, IL-1, and IL-6, which induce 
angiogenesis and synovial hyperplasia by 
stimulating the production of growth factors 
including vascular endothelial growth factor, 
platelet-derived growth factor, fi broblast 
growth factor and insulin-like growth factor, 
resulting in the formation of rheumatoid 
pannus.21 Histologically, rheumatoid 
pannus consists of proliferating synovial 
cells and infl ammatory cells, granulation 
tissue, and fi brotic tissue.15 Aggregates of 
organizing fi brin may also be visible on 
the synovial surface and in the synovial 
fl uid.15 Furthermore, in a rheumatoid joint, 
the synovial architechture and synoviocyte 
phenotypes undergo changes.21
Finally, pannus supersedes the normal 
synovium, and cartilage subjacent to the 
pannus is eroded.15 Cartilage erosion and 
destruction may be mediated by fi broblast-
like synoviocytes.21 Infl ammation aff ects 
chondrocyte function and impairs collagen 
synthesis and cartilage repair. It may also 
attack subarticular bone: bone destruction 
is performed by osteoclasts and regulated by 
the Wnt, RANK ligand, and osteoprotegerin 
pathways.21 Such fi brosis and ossifi cation may 
potentially lead to permanent ankylosis, and 
the destruction of soft  tissue structures may 
result in joint deformities.15
1.4  Epidemiology
RA aff ects approximately 0.5 to 1% of the 
population worldwide, with women 2 to 3 
times as likely as men to develop the disease.30 
Its annual incidence in Finland is estimated 
at 44.5 per 100 000 (58.6 for women, 29.5 for 
men).31 Studies in industrialized countries 
show annual incidences between 5 and 50 
per 100  000,16 with results varying based on 
case identifi cation methods and geographical 
diff erences. RA is especially common in 
northern Europe and North America.16 Age 
at onset is usually between 30 and 70, but at 
no age is one immune. Evidence suggests that 
RA incidence may be declining, with disease 
onset shift ing towards older age groups.32,33
1.5  What is early RA?
Th e signs and symptoms of RA develop over 
a variable period of time, in some cases even 
over several years.34 To predict the outcome 
and prognosis of early infl ammatory arthritis 
at the onset of the symptoms is challenging: 
some patients may achieve remission, while 
others progress to classifi able RA or other 
clinical forms of chronic arthritis.34 For these 
reasons, defi ning the beginning and duration 
of RA explicitly is demanding.
For case identifi cation of incident 
RA, methods are many and heterogenous. 
Th ey identify RA patients with diff erent 
sensitivities and specifi cities, and this is 
likely to be refl ected in the duration of RA 
symptoms before inclusion. In some studies, 
RA onset refers to the onset of any symptom 
attributable to RA or patient-reported 
fi rst joint swelling, and in others, it means 
fulfi llment of RA classifi cation criteria or 
clinical RA diagnosis.35 As a consequence, 
comparison of disease duration between 
studies is challenging. 
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Americal College of Rheumatology (ACR) 
1987 classifi cation criteria has been widely 
used for case identifi cation earlier. Th ese 
criteria were devised for RA classifi cation 
in research,36 not as diagnostic tools, so the 
sensitivity of the ACR 1987 criteria in the 
early phases or mild forms of RA is relatively 
low.37 In 2010, the ACR and the European 
League Against Rheumatism (EULAR) 
developed new classifi cation criteria, aiming 
at earlier patient identifi cation, treatment, and 
study inclusion. Indeed, the ACR/EULAR 
2010 criteria are more sensitive in recognizing 
early RA than are the 1987 criteria.38
In clinical work, rheumatologists 
may make the diagnosis of RA without 
strict fulfi llment of the ACR 1987 or ACR/
EULAR 2010 criteria.34 As a consequence, 
the clinical diagnosis is likely to result in an 
RA population including earlier and milder 
forms of RA than the population provided 
by ACR 1987 criteria. As in the case of ACR/
EULAR 2010 criteria,38 defi ning the onset of 
RA by the clinical diagnosis is likely to lead 
to more sensitivity than with the ACR 1987 
criteria.
Th is work uses the concept of early 
RA relatively liberally, depending on the 
outcome explored. For example, regarding 
atherosclerosis or preatherosclerotic 
changes, focus was mainly on studies in RA 
populations with disease duration under one 
year. On the other hand, when examining 
long-term outcomes such as CV mortality, 
RA was considered as early if disease duration 
was less than ten years. 
1.6  RA pharmacotherapy
Th e target of the modern pharmacotherapy 
in RA is remission, defi ned as the absence 
of clinical symptoms, of active joint 
infl ammation and of erosive or functional 
deterioration. Disease-modifying 
antirheumatic drugs (DMARDs) are a 
collection of agents that reduce synovitis 
and systemic infl ammation by diverse 
mechanisms of action. Th ey comprise 
the core of the RA pharmacotherapy. Th e 
most important conventional DMARD is 
undoubtedly methotrexate, administered 
either perorally or subcutaneously. It can 
be used alone or in combinations with 
other conventional DMARDs such as 
sulfasalazine, hydroxychloroquine, or 
lefl unomide. Biochemically, methotrexate is a 
folic acid antagonist, and it has diverse anti-
infl ammatory eff ects, enhancing extracellular 
adenosine release and inhibiting various 
proinfl ammatory cytokines.39,40
Biological DMARDs such as TNF-α 
blockers, abatacept, rituximab, or tocilizumab 
are considered if response to conventional 
DMARD strategies is insuffi  cient.41 Some of 
them are given by infusion, and others self-
administered by injection. Methotrexate 
is oft en combined with them. Th e most 
important adverse events related to biological 
DMARDs are various infections.
Like DMARDs, glucocorticoids also 
reduce RA-related infl ammation. Because 
of their notorious adverse eff ects in long-
term use, glucocorticoids are suggested for 
only short-term use at their lowest eff ective 
dose, mainly for early and active RA or for 
fl are-ups. Intra-articular glucocorticoids, 
on the other hand, have only minor adverse 
risks, and are a highly eff ective treatment for 
active synovitis.
Non-steroidal anti-infl ammatory drugs 
(NSAIDs) reduce pain and stiff ness in the 
rheumatoid joint, improving function, 
mobility, and quality of life among some RA 
patients with chronic joint pain. Although 
they relieve RA symptoms quite eff ectively, 
they do not improve the course of RA and 
have potentially dangerous eff ects on renal 
function as well as on the gastrointestinal 
and CV systems. Long-term use of NSAIDs, 
especially COX-2 selective inhibitors, has 
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morbidity and mortality.42 Th is has even led 
to the withdrawal of some COX-2 selective 
inhibitors, such as rofecoxib, from the market. 
For these reasons, the long-term use of 
NSAIDs is, in most cases, undesirable. Even in 
short-term use, simultaneous use of proton-
pump inhibitors is a recommendation to 
reduce risk for gastrointestinal bleeding. Most 
importantly, the patient’s renal function, and 
CV and gastrointestinal status always needs 
assessment before prescribing NSAIDs.42 
Besides NSAIDs, treatment options for 
chronic pain in RA include paracetamol and, 
in rare cases, opioid analgesics.
RA treatment guidelines highlight 
the fact that initiating aggressive 
pharmacotherapy early in the disease course 
plays a pivotal role in halting the development 
of erosive joint damage.43 Th is concept of 
an early period in the RA disease course 
when the possibility of achieving complete 
remission with eff ective pharmacotherapy 
is especially high, is oft en referred to as 
the window of opportunity.44 Th e Finnish 
Rheumatoid Arthritis Combination Th erapy 
(FIN-RACo) Trial has promoted from 1999 
a combination of methotrexate, sulfasalazine, 
hydroxychloroquine, and low-dose 
prednisolone in early and active RA, with the 
target designated as swift  remission.45,46 Th is 
treatment protocol is also embedded in the 
heart of Th e Finnish Current Care Guideline 
for RA.45 Biologic agents are generally 
considered in Finland if remission is either 
not achieved or not sustained with the triple 
therapy or another methotrexate-based 
combination therapy.
Although pharmacotherapy is essential 
in the treatment of RA, its optimal care 
requires a multidisciplinary approach, 
including also non-pharmacological 
treatments such as patient education, exercise, 
occupational therapy, physical therapy, diet, 
and, in DMARD refractory cases, surgery.
1.7  Work disability
Without eff ective treatment, RA leads to 
functional disability and diminished work 
capacity. It emerges as loss of productivity 
while at work (presenteeism), lost work 
days (absenteeism), and, possibly, as loss 
of employment and permanent WD. Th ese 
work-related consequences are closely related 
to the social welfare system, and consequently, 
their occurrence diff ers among countries.47,48 
Moreover, studies assessing WD may diff er 
greatly with regard to methodology, causing 
a large heterogeneity in their results. In a 
review including mostly studies from the late 
1990s, the incidence of WD in longitudinal 
studies was 4.3 to 26% when RA duration 
was 2.0 to 2.5 years, and 30 to 50% when RA 
duration was 10 years.47 In a Finnish register 
study from 2000-2007, the 2-year incidence 
of continuous WD in RA was 4.8 to 9.4%, 
and the risk for WD was 2.77 to 3.69 times 
as high as in the age- and sex-specifi c general 
population.49 Furthermore, the same study 
demonstrated a declining incidence of WD in 
successive RA cohorts.49 Variables associated 
with WD in RA include clinical factors such 
as disease severity and physical disability, 
female sex, socioeconomic factors such as 
education, and work-related factors such 
as the physical demands of the job pursued. 
47,50-53
1.8  Mortality 
Evidence for increased mortality rates in RA 
has been accumulating for many decades.54 
Meta-analyses have shown that RA patients 
carry an approximately 45 to 50% increased 
risk for mortality.55,56 Th e major causes of 
death in RA and in the general population 
seem to be similar. Th e specifi c diseases that 
seem to confer excess risk of death include 
hematological, gastrointestinal, respiratory, 
infectious, and, most importantly, CV 
diseases.54,57
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death as in the general population, many 
disease-related factors predict risk of death 
in RA patients. Higher levels of infl ammation 
or disease activity as measured by C-reactive 
protein (CRP) and disease activity score in 
28 joints (DAS28) seem to independently 
predict mortality.58,59 Many studies have 
shown that ACPA- and RF-positivity are 
associated with increased risk of death.54,60 
Other predictors of mortality include extra-
articular manifestations of RA,61 rheumatoid 
cachexia,62 and genetic factors such as the 
HLA-DRB1 gene.63
How mortality rates in RA have changed 
over time remains controversial. On the 
one hand, several studies from diff erent 
continents indicate reductions in mortality 
in successive RA cohorts.60,64-66 On the other 
hand, as a dramatic decline in mortality has 
also occurred in the general population, a 
widening all-cause mortality gap between 
RA patients and the general population has 
even been suggested.59,67 A meta-analysis 
of 11 studies from 1955 to 1995 reported a 
decline in the incidence of all-cause mortality 
but no decrease in standardized mortality 
ratio (SMR) in successive RA cohorts.55 One 
registry study from Finland suggested no 
increased mortality in patients with incident 
RA diagnosed between 2000 and 2007 and 
observed through 2008, the SMR being 0.97 
(95% confi dence interval [CI] 0.91-1.02).60 A 
recent British study found no change in SMRs 
but a sustained excess mortality in successive 
RA or early infl ammatory polyarthritis 
inception cohorts diagnosed in 1990-1994, 
1995-1999, and 2000-2004.68
2  Comorbidities in early RA
2.1  Overview
RA is associated with a wide spectrum of 
coexisting diseases, that is, comorbidities, 
with profound eff ects on many important 
RA outcomes, including quality of life, 
WD, and mortality.7,8,69 Apart from CV 
disease, which is well acknowledged to 
be linked to RA, the patients suff er from 
infections, anemia, lymphoproliferative 
malignancies, gastrointestinal disorders, 
osteoporosis, depression, and various 
autoimmune diseases at a higher rate than 
does the general population. Some of these 
comorbidities may be treatment-associated: 
for example, NSAID use is an important risk 
factor for gastrointestinal ulceration, and 
glucocorticoids predispose to osteoporosis 
and cataract. 
2.2  Cardiovascular disease
2.2.1  Etiology and pathogenesis 
Many cross-sectional and longitudinal 
epidemiological studies have confi rmed, 
among patients with established RA, an 
elevated risk for atherosclerosis, clinical 
CV disease, and CV mortality.70,71 Although 
under wide investigation, the underlying 
causes of the increased CV burden are not yet 
completely clear. Th e association of RA and 
CV disease may originate from both causal 
and non-causal elements. One proposal is 
that RA-specifi c factors such as immune 
dysregulation, systemic infl ammation, 
or treatment with oral glucocorticoids or 
NSAIDs enhance CV risk during the course 
of RA. On the other hand, RA and CV disease 
may share risk factors such as smoking, genes, 
or diet which could elevate the risk for CV 
events already before the onset of RA.63,72-74 
Supporting evidence exists for both of these 
theories, suggesting a combination of the two.
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pathophysiologic mechanisms of CV risk 
in RA is the interplay between systemic 
infl ammation and atherosclerosis. 
Atherogenesis is nowadays recognized not 
as a passive lipid accumulation but an active 
infl ammatory process characterized by 
pathogenetic steps such as endothelial injury, 
recruitment of various infl ammatory cells, 
proliferation of smooth muscle cells, and lipid 
oxidation.75 
An atherosclerotic plaque and an 
RA-aff ected infl amed joint show noteworthy 
similarities in their infl ammatory events 
(Figure 1). Not only the same types of 
infl ammatory cells but also the same 
cytokines such as TNF-α and IL-6 
mediate injury in both atherosclerosis and 
synovitis.76 Neoangiogenesis, expression 
of adhesion molecules, and extracellular 
matrix degradation are also involved in both 
processes.76,77 In addition to infl ammation, 
another factor linking atherosclerosis 
and RA may be autoimmunity: for 
example, citrullinated proteins that can be 
recognized by ACPAs may occur within an 
atherosclerotic plaque.78 Moreover, toll-like 
receptors modulating antibody formation 
in RA reside also in atherosclerotic plaques, 
and autoantibodies against oxidized LDL 
may be involved in the development of both 
atherosclerosis and RA.79 
Although synovium is the harbor 
of infl ammation in RA, when RA is 
active, various amounts of infl ammatory 
cytokines are released into the systemic 
circulation. Th ese cytokines have multiple 
pro-atherogenic eff ects (Figure 2). Firstly, 
cytokines mediate endothelial dysfunction 
by upregulating endothelial adhesion 
molecule expression, attracting leukocytes.80 
Secondly, they impair the insulin sensitivity 
of skeletal muscle and adipose tissue, 
leading to increasing glucose and lipid levels 
in the blood.80 Infl ammation promotes 
pro-atherogenic oxidative modifi cation of 
low-density lipoprotein (LDL) and impairs 
the ability of high-density lipoprotein 
(HDL) particles to remove cholesterol from 
atherosclerotic lesions.81,82 TNF-α raises the 
levels of asymmetric dimethyl-L-arginine 
(ADMA), an endogenous inhibitor of nitric 
oxide synthase and an indicator of oxidative 
stress and CV risk. ADMA, in turn, may 
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Figure 1. Schematic illustration of similarities between the histology and biochemical features of a 
rheumatoid joint and atherosclerotic plaque. 
Abbreviations: RA, rheumatoid arthritis; TNF-α, tumor necrosis factor alpha; IL-1, interleukin-1; 
IL-6, interleukin-6; MMPs, matrix metalloproteinases; LDL, low-density lipoprotein; oxLDL, oxidized 
low-density lipoprotein.
Similar factors between a joint affected
by RA and an atherostatic plaque
9reduce levels of endothelial progenitor cells, 
thereby preventing them from repairing 
endothelial injury.80 Furthermore, TNF-α 
induces the expression of tissue factor on 
monocytes and endothelium, leading to 
increased coagulation.80
2.2.2  Cardiovascular risk in early RA
Since this thesis focuses on comorbidities in 
future and early RA patients, the following 
sections describe recent evidence on CV 
changes closely preceding and following the 
diagnosis of RA. 
2.2.2.1 Traditional cardiovascular risk 
factors
Data are somewhat inconsistent as to whether 
the prevalence of hypertension is higher in RA 
than in the general population.83 Regarding 
established RA, a meta-analysis that included 
seven RA case-control studies failed to 
demonstrate an increase in prevalence of 
hypertension among RA cases compared 
with that of controls.84 Among newly 
diagnosed RA patients, few studies have 
investigated the prevalence of hypertension as 
a primary outcome. In a Swedish prospective 
study of 442 RA patients, prevalence of 
antihypertensive treatment during the 5-year 
period aft er RA diagnosis increased from 
24.5% to 37.4%.85 In a small case-control 
study investigating the extent of coronary 
artery atherosclerosis in RA, hypertension 
prevalence was 67.6% among established RA 
patients, 38.6% among early RA patients, 
and 38.4% among controls.86 Higher disease 
activity is associated with hypertension, and 
furthermore, blood pressure may be reduced 
by successful antirheumatic treatment.87 
Blood pressure levels have been reported as 
covariate data in several studies that show, 
despite their methodological diff erences, 
mainly similar prevalences of hypertension 
in newly onset RA compared with those of 
non-RA controls (Table 1). 
In general, LDL particles expedite 
the formation of atherosclerotic plaque 
by transporting cholesterol into arterial 
walls, whereas HDL particles dampen 
atherosclerosis by eliminating cholesterol 
from the vessel wall. Besides high LDL 
and low HDL cholesterol levels, elevated 
lipoprotein(a) (Lp(a)) levels are a marker 
of CV risk. Reduced HDL cholesterol and 
increased Lp(a) levels correlate with elevated 
infl ammatory activity in RA measured by 
serum CRP levels.84,88 Interestingly, despite 
higher CV risk, active infl ammation in 
RA also leads to a reduction in the levels of 
triglycerides, LDL, and total cholesterol, 
suggesting a paradoxical inversion of the 
relationship between CV risk and lipid 
levels.89 In line with this, an American 
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Figure 2. Proatherogenic processes caused by the release of infl ammatory cytokines into the systemic 
circulation. 
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retrospective cohort study from 2005-2010 
showed a non-linear J-shaped association 
between LDL levels and risk for myocardial 
infarction, the lowest risk being observed 
among patients with LDL between 1.8 and 
2.6 mmol/l.90 Comparable fi ndings have come 
from studies on infl ammatory and infectious 
diseases other than RA.91 
It is not yet fully clear why infl ammation 
aff ects lipid levels in such radical ways, but the 
activation of the reticuloendothelial system 
may play an important role in the changes.89 
In addition to quantitative infl ammation-
related lipid level changes, changes may also 
be qualitative: for example, changes in the 
subfraction composition of HDL may result 
in a decrease in its anti-infl ammatory and 
reverse cholesterol-transport function.91
Similarly, in early RA, many studies 
show levels of HDL cholesterol lower than 
in non-RA controls, whereas results for 
total or LDL cholesterol have been more 
ambiguous (Table 1). Some have observed a 
typical proatherogenic lipid profi le in early 
RA compared with control profi les, more 
specifi cally higher serum levels of total 
cholesterol, LDL cholesterol, and triglycerides 
but lower serum HDL cholesterol92 as well 
as smaller LDL particle size.93 Other studies, 
however, suggest in early RA relatively low 
levels of both total cholesterol and HDL 
cholesterol.94 Despite this heterogeneity, a 
common feature in many studies has been 
higher atherogenic total cholesterol/HDL 
ratio in early RA. 
Antirheumatic pharmacotherapy and 
subsequent control of disease activity seems 
to improve blood lipids by raising HDL 
cholesterol.92,94 Th is was recently shown 
in a 24-week randomized controlled trial 
involving 459 patients with early, untreated 
RA: shortly aft er initiation of either 
methotrexate monotherapy, of a combination 
of methotrexate and etanercept, or of triple 
therapy; the levels of both total, LDL, and 
HDL cholesterol increased, and the ratio of 
total cholesterol to HDL cholesterol fell.95 
Furthermore, Lp(a) levels decrease aft er 
inhibition of IL-6 signaling with biologic 
agents.96 Although antirheumatic treatment 
may raise total and LDL cholesterol and 
thus theoretically elevate CV risk, this is 
less likely to represent an increased CV risk 
than a response to successful suppression of 
infl ammation.89
Interestingly, some have observed 
derangements in lipid profi les even in 
preclinical phases of RA. Van Halm and 
coworkers reported that 79 blood donors with 
future RA showed a more atherogenic lipid 
profi le than did controls even 10 years prior 
to clinical eruption of RA (Table 1).97 One 
study within the Rochester Epidemiology 
Project showed that levels of total and LDL 
cholesterol decreased during the 5 years 
before the fulfi llment of the ACR 1987 
criteria in 577 RA patients, but not among 
540 non-RA controls. HDL cholesterol levels 
in the RA group, however, remained similar, 
resulting in a decreasing atherogenic total 
cholesterol/HDL ratio before RA onset.98 
Th e systemic infl ammatory burden 
in RA may enhance insulin resistance 
and therefore promote type II diabetes 
mellitus.99-101 Initial data suggest higher 
fasting insulin levels and more insulin 
resistance even during the fi rst year of RA 
than found among non-RA controls.102 
Furthermore, the insulin-resistant state may 
be more severe among patients with high 
versus moderate disease activity.102 Besides 
systemic infl ammation, glucocorticoid use 
in RA may promote insulin resistance.103 
Whether diabetes is more common in RA 
than in the general population, the consensus 
is not yet unanimous – reports both 
support4,104 and oppose105,106 an association 
between RA and both type I and type II 
diabetes. A meta-analysis of 15 case-control 
studies suggests that in RA the prevalence of 
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diabetes is increased, although studies were 
statistically signifi cantly heterogeneous.84 
Regarding RA and type I diabetes mellitus, 
convincing evidence from recent population-
based studies indicates a positive association 
between these diseases.4,107 Th e frequency of 
type I diabetes, however, was similar among 
1,460 Finnish RA patients when compared 
with that of the general middle-aged 
population in Finland.106 Interestingly, in a 
preliminary study of 11 non-diabetic patients 
with rheumatoid disease, inhibition of IL-6 
signaling with biologic agents improved 
insulin sensitivity.96
Smoking is more prevalent among 
RA patients than among the general 
population84,113,114 in part because smoking is a 
risk factor for ACPA-positive RA.115 Smoking 
may be even more prevalent among those who 
will have RA in the future than among those 
who have already been diagnosed, as implied 
by a Swedish prospective study in which the 
prevalence of smoking decreased from 29.8% 
to 22.4% during the 5 years following the RA 
diagnosis.85
Obesity is recognized nowadays as 
a chronic low-grade infl ammatory state, 
mediated by adipokines produced by 
adipose tissue.116 In early RA, an unhealthy 
body-composition phenotype may be more 
frequent than in controls, as indicated by 
lower appendicular lean mass, higher body 
fat mass, and higher truncal fat mass.111,112 
Metabolic syndrome seems to be more 
prevalent in established RA than in non-RA 
controls.117 Th is may also be the case in early 
RA, as indicated by a study among 154 RA 
patients, in which the prevalence of metabolic 
syndrome was 42% in patients with a median 
RA duration of 20 years, 31% for a median 
RA duration of two years, and 11% in non-RA 
controls (P<0.001).108 Again, a possible 
mediator for this association is the frequent 
use of glucocorticoids in RA. Abnormal body 
fat composition in RA is not an innocent 
bystander but is associated with higher CRP 
levels and a more severe disease course.118,119
2.2.2.2 Non-traditional cardiovascular risk 
factors
Although traditional CV risk factors 
contribute to development of CV disease also 
among RA patients, they do not fully explain 
the excess CV risk.105 Th is has led to the 
theory that RA patients carry additional risk 
factors for CV disease. Th e two main culprits 
indicated to induce atherosclerotic damage in 
systemic rheumatic diseases are infl ammation 
and autoimmunity.120,121 Th ese are activated 
prior to the onset of RA symptoms122-124 
and may enhance atherosclerosis already in 
preclinical or early phases of RA.125 Traditional 
and non-traditional risk factors do not lead 
to increased CV risk independently of each 
other: for example, both insulin resistance and 
atherogenic lipid levels increase with higher 
CRP values,102,125,126 and insulin resistance has 
been linked to seropositivity.127
Markers of systemic infl ammation 
and disease activity might be useful when 
evaluating in RA the magnitude of CV risk. 
An American retrospective cohort study 
on 44,000 RA patients found a CRP level of 
>10 mg/L compared with <1 mg/L and an 
erythrocyte sedimentation rate (ESR) level 
of >42 mm/h compared with <14 mm/h to 
be associated with a twofold risk for MI.90 
In a recent Swedish ten-year observational 
study among 741 patients with early RA, the 
area under the curve for both CRP and ESR 
values was associated with higher CV disease 
risk.128 In a Swedish prospective 5-year study 
among 442 patients with newly diagnosed 
RA, independent predictors of a CV event 
included raised ESR at baseline, higher 
cumative disease activity, and progression 
of extra-articular disease.85 Subclinical 
atherosclerotic changes such as higher carotid 
intima-media thickness (IMT) and impaired 
vasodilatory responses have been generally 
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shown to associate with higher CRP, ESR, and 
DAS among early RA patients,129-133 although 
some studies have demonstrated no such 
association.134,135
As to immune-mediated mechanisms, 
a plethora of epidemiological data show that 
RF and ACPA positivity are associated with 
increased risk for CV events in RA.128,136-138 
Interestingly, in a study on 40 patients with 
early RA, antibodies against oxidized LDL 
independently predicted atherosclerosis as 
measured by carotid ultrasound (p=0.0089).131 
In the Swedish 5-year prospective study, 
however, CV events were not linked to RF, 
ACPA, or anti-nuclear antibodies during 
the fi rst years of RA.85 Still, the same group 
found that low longitudinal levels of IgM 
anti-phosphorylcholine, an antibody that 
may protect from atherosclerosis and chronic 
infl ammation, may independently predict 
the presence of bilateral carotid plaque,139 
a fi nding in line with fi ndings in non-RA 
populations.140 
2.2.2.3 Preatherosclerotic processes
Endothelial dysfunction, an early step 
of atherogenesis, is linked to increased 
expression of adhesion molecules, production 
of proinfl ammatory and prothrombotic 
molecules, oxidative stress, diminished 
production of nitric oxide, and impaired 
modulation of vascular tone.121 It can 
be assessed by measuring endothelium-
dependent vasodilatory responses in 
both micro- and macrocirculation.121 
Endothelial dysfunction seems to be more 
prevalent in established RA patients than in 
healthy controls, and to be associated with 
infl ammation.141 As to the fi rst few years of 
RA, the state of endothelial function is still 
unclear (Table 2, Figure 3). 
Th ree studies have found among 
patients with newly diagnosed untreated 
RA signifi cantly impaired brachial artery 
vasodilatory responses.130,134,142 In all 
these studies, endothelial dysfunction 
was reversed aft er 6 to 12 months of 
antirheumatic drug therapy.130,142,143 In line 
with these results, coronary fl ow reserve, 
as measured by dipyridamole transthoracic 
stress echocardiography, may be lower 
among recent-onset RA patients than 
among controls.144 As with brachial artery 
vasodilatory responses, aft er treatment with 
DMARDs, vascular function of coronary 
arteries improved.135
Noteworthy is that these studies 
had relatively small numbers of patients 
(Table 2). Besides, in one population of 
79 RA patients whose symptoms had 
developed in less than one year, brachial 
artery endothelium-dependent dilation 
was preserved both at baseline and aft er 18 
months of follow-up.145 Furthermore, an 
observational study among 18 RA patients 
with median symptom duration of only 
two months showed preserved micro- and 
macrovascular endothelial function.146 Th e 
same study, however, revealed increased 
levels of molecular markers of endothelial 
damage and abnormal endothelium-
independent vasodilatory responses 
(induced by sublingual glyceryl trinitrate for 
macrovascular assessment and iontophoresis 
of sodium nitroprusside for microvascular 
assessment).146 A study among 15 patients 
with early RA and low-grade infl ammation 
(CRP <20mg/dl) found no diff erences 
between patients and controls in skin 
microvascular function.147 In the light of these 
studies, whether endothelial dysfunction is 
present in excess during the fi rst years of RA 
remains inconclusive. 
2.2.2.4 Subclinical atherosclerosis
Non-invasive methods for assessing 
the extent of atherosclerosis include 
echocardiography of the carotid arteries and 
evaluation of coronary artery calcifi cation 
in computer tomography scans. Th e related 
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measurements, more specifi cally carotid 
IMT and coronary artery calcifi cation 
score, are strongly associated with risk for 
CV disease.148,149 Carotid IMT has been 
quite extensively studied in early RA, and 
four129,131,132,144 of the seven129,131,132,135,144,145,150 
case-control studies included in this review 
found IMT to be signifi cantly higher in RA 
patients with a disease duration of under one 
year than in controls (Table 2, Figure 3). With 
longer disease duration, the carotid IMT may 
increase even further.150 In line with this, 
coronary artery calcifi cation may be more 
prevalent and severe in RA cohorts of long-
standing disease than among those with RA 
for less than fi ve years.86
Again, confl icting results exist: the 
79 early-RA patients who had preserved 
endothelial function had no higher carotid 
IMT values than did controls at baseline.145 
During 18 months of follow-up, however, 
their carotid IMT rapidly increased, with no 
similar increase apparent among controls.145
Carotid plaque prevalence is another 
marker of atherosclerosis and predictor of CV 
events that can be measured by ultrasound 
examination.151 Two studies observed more 
prevalent plaques in the carotid arteries of 
RA patients with disease duration less than 
one year than among healthy controls,131,132 
whereas one study found no diff erence 
between early RA patients and controls.129 
In established RA, carotid plaque prevalence 
associates with disease activity.152
To conclude, it seems that morphological 
atherosclerotic changes occur rapidly aft er or 
even prior to onset of RA symptoms (Figure 
3) and are likely to become aggravated along 
with longer disease duration.
2.2.2.5 Subclinical myocardial damage
Several echocardiographic studies have 
demonstrated that RA patients without 
clinically evident heart disease present with 
more left  ventricular fi lling abnormalities 
than do healthy controls.153-155 Moreover, 
diastolic dysfunction seems to correlate with 
disease duration, suggesting a subclinical 
myocardial involvement with the progression 
of RA.153-155 In addition, RA patients are more 
likely to have higher systolic pulmonary artery 
pressures, increased left  ventricular mass 
and larger left  atrial size than controls across 
studies, but their left  ventricular ejection 
fractions have usually been similar.156,157 
Interestingly, recent studies assessing 
myocardial function by speckle-tracking 
echocardiography strain imaging have shown 
reduced myocardial strain in patients with 
both early158 and established159 RA without 
known CV disease. In early and untreated 
RA, left  ventricular function measured by 
global longitudinal systolic strain correlates 
with disease activity and ACPA-positivity.160 
Of note, myocardial infl ammation and 
fi brosis in cardiac magnetic resonance scans 
may be frequent in RA patients without 
known cardiac disease, and be linked to RA 
disease activity.161
NT-proBNP is a marker of ventricular 
dysfunction and CV risk that has prognostic 
signifi cance both in heart failure and acute 
coronary syndrome. A study of 90 patients 
with early RA (duration < 5 years), 69 with 
long-standing RA (duration > 10 years), and 
88 controls has indicated that NT-proBNP 
concentrations are elevated also in early RA 
when compared with control values, although 
the increase is even more pronounced 
in established disease.162 Patients with 
established RA without heart failure also 
show elevated high-sensitivity troponin I 
levels.163 
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Figure 3. Overview of studies on subclinical CV changes near RA onset (updated from a review 
by Kerola et al.,13 adapted by permission from the BMJ Publishing Group Limited). Red bars show 
increased CV risk, green bars unincreased risk. Starting point and length of bars represent observation 
period. Asterisks indicate studies not included in the original publication.
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2.2.2.6 Symptomatic cardiovascular disease
Clinical CV disease is estimated to be 1.5 to 2 
times as prevalent in established RA as in the 
general population, and the CV disease risk 
in RA is comparable to that exerted by type 
2 diabetes mellitus.165,166 Similar phenomena 
appear in the early years of RA. For instance, 
the rates of hospital admissions for CV 
disease among patients with infl ammatory 
polyarthritis of less than seven years are 
double those of the general population.167 In 
a cohort of 553 newly-onset RA patients from 
Rochester, Minnesota, USA, the absolute 
ten-year risk for a CV event was as high as 
that of non-RA patients who were 5 to 10 
years older.168 
Many temporal aspects of RA-related 
CV risk are not yet fully clarifi ed. Initial 
data are controversial as to whether CV 
disease is more prevalent than expected 
before RA onset.72,169 CHD in established 
RA may occur at a younger age than in the 
general population,168 and the rate ratio for 
CV events and death is highest in young RA 
patients, albeit the rate diff erence increases 
with age.165 Young age at RA onset may be 
associated with increased risk of CV death.138 
Furthermore, RA duration may act as a risk 
factor for CV disease, since long-standing 
disease leads to longer exposure to chronic 
infl ammation.86 A recent study involving 
855 RA patients discovered, however, that 
disease activity over time rather than disease 
duration may contribute to excess CV risk, 
since neither occurrence nor hazard for a CV 
event correlated independently with disease 
duration.170
RA may present with extra-articular 
manifestations that involve the CV system 
such as vasculitides, pericarditis, pericardial 
eff usion, valvular heart disease, conduction 
defects, and myocardial fi brosis or 
amyloidosis. Th ese diseases are relatively rare 
complications of RA, and are not this study’s 
main focus, which is atherosclerotic CV 
disease and other common CV conditions.
2.2.2.7 Coronary heart disease and stroke
According to a recent systematic review 
and a meta-analysis, the risk for myocardial 
infarction in RA is 2.1-fold and for stroke 
1.9-fold that of the general population.171 
Another meta-analysis, however, indicated 
no increased risk for stroke but only for 
myocardial infarction.172 In a cohort of 
approximately 4,000 RA patients from 
17 countries, the average prevalence of 
myocardial infarction or stroke was 6.6%, and 
prevalence by country was generally higher 
in European countries and in the US than in 
Asia or South America.173 
Th e CHD phenotype may diff er among 
patients with and without RA. Data from 
the Rochester Epidemiology project have 
shown RA patients to be less likely to 
report symptoms of angina and more likely 
to experience unrecognized myocardial 
infarction and sudden cardiac death than were 
non-RA controls.169 Moreover, RA patients 
may exhibit poorer long-term outcomes aft er 
myocardial infarction, despite similar rates 
of reperfusion therapy and cardioprotective 
medications.174
RA patients may carry an increased risk 
for CHD already in the proximity of the RA 
diagnosis (Figure 3).175,176 Maradit-Kremers 
and coworkers conducted a population-
based cohort study in which they showed 
that RA patients were already at increased 
risk for myocardial infarction during the 
two-year period before fulfi llment of the 
ACR 1987 criteria for RA.169 Holmqvist and 
coworkers, however, in two large Swedish 
cohorts, found no increased risk for CHD 
before onset of RA symptoms,72 whereas 
their subsequent investigation disclosed 
an increased myocardial infarction risk 
aft er one year following fulfi llment of ACR 
criteria for RA.175 Supporting these fi ndings, 
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Figure 4. Overview of studies on symptomatic CV disease risk during the fi rst decade of RA (updated 
from a review by Kerola et al.,13 adapted by permission from the BMJ Publishing Group Limited). Red 
bars represent increased CV risk compared with controls, green bars unincreased risk. Follow-up for 
the fading bars continues beyond the scale (Tables 3, 4). Asterisks indicate studies not included in the 
original publication.
 
-4 -2 0 2 4 6 8 10 12
Goodson 2002 (RF -) [191]
Goodson 2002 (RF +) [191]
Goodson 2005 [190]
Young 2007 [189]
Naz 2008 (RF -) [138]
Naz 2008 (RF+) [138]
Franklin 2010 [167]
Humphreys 2014 [68]*
CV death
Nicola 2005 [178]
Congestive heart Failure
 Maradit-Kremers 2005 [169]
Holmqvist 2009 [72]
Holmqvist 2010 [175]
Lindhardsen 2011 [177]
Coronary heart disease
Maradit-Kremers 2008 [168]
Franklin 2010 [167]
CV disease
Years from symptom onset 
Gonzalez 2008 [105] 
22
Review of the literature
Ta
bl
e 3
. S
tu
di
es
 o
n 
sy
m
pt
om
at
ic
 C
V
 d
ise
as
e n
ea
r t
he
 o
ns
et
 o
f R
A
 (u
pd
at
ed
 fr
om
 a 
re
vi
ew
 b
y 
Ke
ro
la
 et
 al
.,1
3  a
da
pt
ed
 b
y 
pe
rm
iss
io
n 
fro
m
 B
M
J P
ub
lis
hi
ng
 
G
ro
up
 L
im
ite
d)
. A
ste
ris
ks
 in
di
ca
te
 st
ud
ie
s n
ot
 in
clu
de
d 
in
 th
e o
rig
in
al
 p
ub
lic
at
io
n.
Au
th
or
, y
ea
r 
(r
ef
.)
Po
pu
la
tio
n 
st
ud
ie
d
RA
 d
ia
gn
os
is
 P
at
ie
nt
s
C
on
tr
ol
s
Ti
m
in
g 
of
 en
d-
po
in
t 
ob
se
rv
at
io
n
Ev
al
ua
tio
n 
m
et
ho
d
Re
su
lts
CV
 d
ise
as
e
Fr
an
kl
in
 2
01
0 
[1
67
]
N
O
A
R-
co
ho
rt
IP
: ≥
2 
sw
ol
le
n 
jo
in
ts 
≥4
 w
k.
 
Ex
clu
sio
n 
if 
no
t 
RA
.
80
0
Th 
e 
N
or
fo
lk
 
po
pu
la
tio
n
M
ed
ia
n 
7.
0 
yr
s f
ro
m
 
RA
 in
ci
de
nc
e d
at
e 
(in
te
rq
ua
rt
ile
 ra
ng
e 
5.
8–
8.
1)
. 
CV
 d
ise
as
e a
dm
iss
io
n 
id
en
tifi
 e
d 
fro
m
 re
co
rd
s o
f a
 lo
ca
l a
cu
te
 ca
re
 
ho
sp
ita
l
RR
 fo
r C
V
 d
ise
as
e a
dm
iss
io
n 
w
as
 1
.9
, 
CH
D
 1
.9
, s
tro
ke
 1
.1
 (n
ot
 si
gn
ifi 
ca
nt
), 
al
l 
va
sc
ul
ar
 d
ise
as
e a
dm
iss
io
n 
2.
0.
 
M
ar
ad
it-
Kr
em
er
s 2
00
8 
[1
68
]
Ro
ch
es
te
r, 
M
in
ne
so
ta
, 
re
sid
en
ts 
 
AC
R 
19
87
 
cr
ite
ria
55
3
57
4
0-
10
 y
rs
 si
nc
e R
A
 
in
ci
de
nc
e d
at
e
C
om
bi
ne
d 
CV
 o
ut
co
m
e i
nc
lu
di
ng
 
co
ro
na
ry
 re
va
sc
ul
ar
iz
at
io
n,
 M
I, 
CH
F 
an
d 
CV
 d
ea
th
El
ev
at
ed
 ab
so
lu
te
, e
xc
es
s, 
an
d 
re
lat
iv
e 
10
-y
r r
isk
 o
f C
V
 d
ise
as
e. 
In
ci
de
nc
e o
f 
th
e o
ut
co
m
e w
as
 el
ev
at
ed
 so
on
 aft
 e
r R
A
 
in
ci
de
nc
e d
at
e.
G
on
za
le
z 2
00
8 
[1
05
]
Ro
ch
es
te
r, 
M
in
ne
so
ta
, 
re
sid
en
ts 
 
AC
R 
19
87
 
cr
ite
ria
60
3
60
3
RA
 in
ci
de
nc
e d
at
e
A
ng
in
a p
ec
to
ris
, C
H
D
, M
I, 
he
ar
t 
fa
ilu
re
, e
tc
. b
ef
or
e i
nc
id
en
ce
 d
at
e
Si
m
ila
r p
re
va
le
nc
e o
f C
V
 d
ise
as
e.
C
or
on
ar
y h
ea
rt
 d
ise
as
e 
Lj
un
g 
20
14
 
[1
82
]*
Sw
ed
ish
 R
A
 
co
ho
rt
s b
as
ed
 
on
 th
e N
at
io
na
l 
Pa
tie
nt
 R
eg
ist
er
 
an
d 
th
e S
w
ed
ish
 
Bi
ol
og
ic
s R
eg
ist
er
tw
o 
or
 m
or
e 
cli
ni
ca
l v
isi
ts 
or
 
ho
sp
ita
liz
at
io
ns
 
w
ith
 R
A
 as
 a 
di
ag
no
sti
c c
od
e
7,
70
4 
TN
Fi
 
ex
po
se
d,
 
23
,1
12
 
bi
ol
og
ic
s-
na
iv
e
38
,5
20
RA
 d
ur
at
io
n 
no
t 
de
fi n
ed
. A
t i
nc
lu
sio
n,
 
19
.6
%
 v
s. 
16
.7
%
 h
ad
 
ha
d 
RA
 >
10
yr
s, 
an
d 
m
ed
ia
n 
fo
llo
w
-u
p 
w
as
 
3.
9 
vs
. 2
.7
 y
rs
 in
 T
N
Fi
 
ex
po
se
d 
vs
. b
io
lo
gi
c-
na
iv
e g
ro
up
.
A
ny
 fi 
rs
t A
CS
; d
efi
 n
ed
 as
 p
rim
ar
y 
di
sc
ha
rg
e d
ia
gn
os
is 
of
 ac
ut
e M
I, 
un
st
ab
le
 an
gi
na
 p
ec
to
ris
, o
r a
cu
te
 
M
I a
s u
nd
er
ly
in
g 
ca
us
e o
f d
ea
th
Ri
sk
 fo
r A
CS
 in
 b
ot
h 
TN
Fi
 u
se
rs
 an
d 
bi
ol
og
ic
s-
na
iv
e p
at
ie
nt
s
w
er
e s
ig
ni
fi c
an
tly
 in
cr
ea
se
d 
co
m
pa
re
d 
to
 g
en
er
al
 p
op
ul
at
io
ns
’: 
H
R 
fo
r T
N
Fi
-
ex
po
se
d 
w
as
 1
.6
1 
an
d 
fo
r t
he
  b
io
lo
gi
cs
-
na
ïv
e p
at
ie
nt
s 2
.0
3.
K
ha
n 
20
13
 
[1
83
]*
Ba
se
d 
on
 in
pa
tie
nt
 
ho
sp
ita
l d
at
ab
as
e, 
N
ew
 Z
ea
la
nd
IC
D
-9
 co
de
 7
14
 
an
d 
IC
D
-1
0 
co
de
s M
5-
M
6 
65
3
 
m
ea
n 
RA
 d
ur
at
io
n 
5.
8 
yr
s
U
ns
ta
bl
e a
ng
in
a, 
M
I, 
ca
rd
ia
c a
rr
es
t, 
or
 ca
rd
ia
c d
ea
th
 id
en
tifi
 e
d 
fro
m
 
ho
sp
ita
l r
ec
or
ds
; I
CD
-9
 co
de
s 4
10
-
41
3,
 IC
D
-1
0 
co
de
s I
20
-2
1
Pr
ob
ab
ili
ty
 o
f a
n 
CV
 ev
en
t i
n 
1 
vs
. 1
0 
yr
 aft
 e
r d
ia
gn
os
is 
w
as
 0
.6
4%
 v
s. 
9.
4%
. 
M
ed
ia
n 
tim
e t
o 
fi r
st 
CV
 ev
en
t w
as
 2
.5
3 
ye
ar
s (
ra
ng
e 0
.0
2–
8.
31
).
Li
nd
ha
rd
se
n 
20
11
 [1
77
]
D
an
ish
 
po
pu
la
tio
n 
 
IC
D
 co
de
s 
M
5-
M
6 
an
d 
pr
es
cr
ip
tio
n 
of
 
D
M
A
RD
s
10
47
7 
to
ta
l, 
29
5 
in
 
ca
se
-c
on
tro
l 
stu
dy
Po
pu
lat
io
n
Tr
ea
tm
en
t d
ur
at
io
n 
0-
3 
yr
s
M
I
O
R 
fo
r M
I w
as
 1
.7
 d
ur
in
g 
yr
s 0
-3
.
H
ol
m
qv
ist
 2
01
0 
[1
75
]
Sw
ed
ish
 E
RA
R 
co
ho
rt
AC
R 
19
87
 
cr
ite
ria
74
69
37
02
4
D
ia
gn
os
is 
<1
8 
m
os
 
aft
 e
r s
ym
pt
om
 o
ns
et
, 
m
ed
ia
n 
6 
m
os
M
I
N
o 
di
ff e
re
nc
e a
t 1
 y
r. 
At
 1
-4
 y
rs
 R
R 
w
as
 
1.
6,
 an
d 
at
 5
-1
2 
yr
s R
R 
1.
6.
 N
o 
di
ff e
re
nc
e 
by
 R
F 
st
at
us
.
H
ol
m
qv
ist
 2
00
9 
[7
2]
Sw
ed
ish
 E
A
R 
an
d 
EI
RA
 co
ho
rt
AC
R 
19
87
 
cr
ite
ria
84
54
 an
d 
20
25
42
26
7 
an
d 
27
60
Be
fo
re
 sy
m
pt
om
 o
ns
et
N
at
io
nw
id
e r
eg
ist
er
 an
d 
se
lf-
re
po
rt
ed
  C
H
D
 ev
en
ts
N
o 
in
cr
ea
se
 in
 M
I, 
an
gi
na
 p
ec
to
ris
, o
r 
to
ta
l C
H
D
 p
rio
r t
o 
RA
. R
F 
st
at
us
 d
id
 n
ot
 
m
od
ify
 th
is 
la
ck
 o
f e
xc
es
s r
isk
.
 M
ar
ad
it-
Kr
em
er
s 2
00
5 
[1
69
]
Ro
ch
es
te
r, 
M
in
ne
so
ta
, 
re
sid
en
ts 
 
AC
R 
19
87
 
cr
ite
ria
60
3
60
3
2-
yr
 p
er
io
d 
be
fo
re
 th
e 
RA
 d
ia
gn
os
is
C
om
bi
ne
d 
CH
D
 ev
en
t
O
R 
fo
r u
nr
ec
og
ni
ze
d 
M
I w
as
 5
.5
, f
or
 
ho
sp
ita
liz
ed
 M
I 3
.4
0,
 an
d 
fo
r a
ng
in
a 
pe
ct
or
is 
0.
59
.
23
Au
th
or
, y
ea
r 
(r
ef
.)
Po
pu
la
tio
n 
st
ud
ie
d
RA
 d
ia
gn
os
is
 P
at
ie
nt
s
C
on
tr
ol
s
Ti
m
in
g 
of
 en
d-
po
in
t 
ob
se
rv
at
io
n
Ev
al
ua
tio
n 
m
et
ho
d
Re
su
lts
C
on
ge
st
iv
e h
ea
rt
 fa
ilu
re
 
N
ic
ol
a 2
00
5 
[1
78
]
 
Ro
ch
es
te
r, 
M
in
ne
so
ta
, 
re
sid
en
ts 
 
AC
R 
19
87
 
cr
ite
ria
57
5
58
3
6-
46
 y
rs
 fr
om
 
di
ag
no
sis
 (m
ed
ia
n 
fo
llo
w
-u
p 
11
.8
 y
rs
)
Fr
am
in
gh
am
 H
ea
rt
St
ud
y 
cr
ite
ria
1.
7-
fo
ld
 in
ci
de
nc
e o
f C
H
F. 
Ri
sk
 h
ig
he
r 
am
on
g 
th
e R
F+
.
*S
tu
di
es
 n
ot
 in
clu
de
d 
in
 th
e o
rig
in
al
 p
ub
lic
at
io
n.
 
Ab
br
ev
ia
tio
ns
: R
A
, r
he
um
at
oi
d 
ar
th
rit
is;
 C
V,
 ca
rd
io
va
sc
ul
ar
; A
CR
, A
m
er
ic
an
 C
ol
le
ge
 o
f R
he
um
at
ol
og
y;
 C
H
D
, c
or
on
ar
y 
he
ar
t d
ise
as
e; 
M
I, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 y
r, 
ye
ar
; C
H
F, 
co
ng
es
tiv
e h
ea
rt
 fa
ilu
re
; T
N
Fi
, T
N
F 
al
ph
a i
nh
ib
ito
rs
; A
CS
, a
cu
te
 co
ro
na
ry
 sy
nd
ro
m
e; 
N
O
A
R,
 th
e N
or
fo
lk
 A
rt
hr
iti
s R
eg
ist
er
; I
P, 
in
fl a
m
m
at
or
y 
po
ly
ar
th
rit
is;
 
RR
, r
isk
 ra
tio
; O
R,
 o
dd
s r
at
io
; E
A
R,
 E
ar
ly
 A
rt
hr
iti
s R
eg
ist
er
; E
IR
A
, E
pi
de
m
io
lo
gi
ca
l I
nv
es
tig
at
io
n 
of
 R
he
um
at
oi
d 
A
rt
hr
iti
s; 
RF
, r
he
um
at
oi
d 
fa
ct
or
; E
RA
R,
 E
ar
ly
 R
he
um
a-
to
id
 A
rt
hr
iti
s R
eg
ist
er
; m
o,
 m
on
th
; I
CD
, I
nt
er
na
tio
na
l C
la
ss
ifi 
ca
tio
n 
of
 D
ise
as
es
; W
H
O
, W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n;
 B
P, 
bl
oo
d 
pr
es
su
re
; J
N
C,
 Jo
in
t N
eg
ot
ia
tin
g 
C
om
m
it-
te
e
Review of the literature
24
a Danish register study revealed an odds ratio 
for myocardial infarction of 1.7 among RA 
patients with treatment duration of less than 
three years.177 
2.2.2.8 Congestive heart failure
Patients with established RA are at increased 
risk for CHF and this contributes to the excess 
mortality in RA.178,179 Risk for heart failure 
is associated with certain RA characteristics 
such as RF positivity, ESR levels, and 
severe extra-articular manifestations.180 
Compared to that of the general population, 
their presentation of heart failure may be 
more subtle, with fewer typical signs and 
symptoms.181 In addition, their left  ventricular 
systolic function is more likely to be preserved 
(ejection fraction ≥50%).181
Elevated risk for CHF may also occur 
in early RA. In a population-based study of 
575 RA patients within the framework of 
the Rochester Epidemiology project, relative 
risk for CHF remained fairly constant, 
almost twice as high as among the controls, 
throughout the long follow-up of 6 to 46 
years.178 Cumulative incidence of CHF had 
already begun to rise more sharply among 
the RA group aft er the fulfi llment of ACR 
1987 criteria for RA.178 Furthermore, a greater 
percentage of RA patients were excluded 
from the study because of pre-existing CHF, 
implying that CHF may already be more 
frequent among them before the clinical 
eruption of RA.178
2.2.2.9 Cardiac arrhythmias
RA patients are at increased risk of sudden 
cardiac death,169 implying that their increased 
incidence of malignant arrhythmias may 
contribute to their excess mortality.184 
Th e prevalences in RA of two important 
arrhythmogenic conditions, CHD and CHF, 
are increased, thus indirectly promoting 
arrhythmias. Nevertheless, cardiomyocyte 
electrophysiology may be directly aff ected by 
infl ammation.184 A considerable number of 
studies show that two important risk factors 
for life-threatening arrhythmias, that is, 
CV autonomic dysfunction and ventricular 
repolarization abnormalities, are excessive 
among RA patients as measured by heart 
rate variability analysis, heart-rate-corrected 
QT-interval, and QT-interval dispersion.184,185 
Th ese mechanisms may underlie the 
increased risk of sudden cardiac death in RA 
populations.
Infl ammation may drive the 
pathogenesis of atrial fi brillation, the most 
common sustained arrhythmia in the general 
population.186 To date, two large cohort 
studies have evaluated the risk for atrial 
fi brillation in RA. A Danish study including 
18,000 patients with RA disclosed a 40% 
higher incidence of atrial fi brillation than 
that of the general population. Moreover, they 
observed higher relative risks in younger age 
groups, but higher absolute risk diff erences in 
older groups.187 A study of nearly 21,000 RA 
patients from the USA revealed an unadjusted 
incidence rate ratio for atrial fi brillation of 
1.4, but aft er adjustment for comorbidities, 
medications, and healthcare use, no increased 
risk for atrial fi brillation was associated with 
RA.188 Both of these studies were conducted 
among cohorts with established RA, and no 
studies to date have assessed the risk for atrial 
fi brillation in early RA.
2.2.2.10 Cardiovascular mortality
A recent meta-analysis of observational 
studies on CV mortality in RA reported a 50% 
increase in risk of CV death in comparison 
to that of the general population.1 Another 
meta-analysis showed the risk for fatal 
myocardial infarction in RA to be increased 
by almost 80%, whereas risk for fatal stroke 
was increased by 46%.171 However, in the 
former meta-analysis, if considering only 
inception cohorts, risk of CV death was not 
elevated.1
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Studies of RA inception cohorts have 
displayed contradictory results as to whether 
CV mortality is increased in the early years of 
RA. In one British multicenter study, mortality 
was increased within the fi rst seven years aft er 
RA diagnosis, and CHD appeared to be a key 
promoter of this early excess mortality.189 
A study of the Norfolk Arthritis Register 
cohort from the UK showed that patients 
diagnosed in 1990-1994 with infl ammatory 
polyarthritis had increased CV mortality 
during a median follow-up of 11.4 years, and 
that, in seropositive patients, their increased 
CV mortality was already apparent fi ve years 
aft er symptom onset (SMR of 1.93, 95% CI 
1.08-3.19).138 However, a cohort identifi ed 
from the same register but diagnosed in 
1995-1999 appeared to have no increased 
CV mortality during the fi rst seven years of 
infl ammatory polyarthritis, neither in the 
seropositive nor the seronegative subgroup.167 
Th e most recent analysis from the same 
register but including patients from 1990-
1994, 1995-1999, and 2000-2004 revealed no 
signifi cant elevation in 7-year CV mortality 
in the early infl ammatory polyarthritis or RA 
cohorts as a whole.68 In the antibody-positive 
subgroup, however, the risk of CV death was 
almost doubled (SMR 1.87, 95% CI 1.30-
2.69).68 A total of six studies that assessed CV 
mortality rates among inception cohorts with 
some form of arthritis was found,68,138,167,189-191 
and three of them138,189,191 suggested a slightly 
increased risk of CV death during the fi rst 
decade of the disease (Table 4, Figure 4). 
What therefore remains controversial is how 
early the CV mortality rates in RA actually 
begin to rise.
During the past few decades, improved 
treatment strategies controlling infl ammation 
have reduced RA disease activity considerably. 
Evidence to fully confi rm a reduction in 
all-cause or CV mortality in established RA 
over time, however, is still lacking. A meta-
analysis of cohort studies including mostly 
cases with established RA reported that SMR 
for CV death did not change between 1945 
and 1995, the pooled SMR being 1.6.57 In a 
large American study, mortality due to acute 
myocardial infarction declined from the 1970s 
to the 1990s, and patients with RA diagnosed 
aft er the 1990s had no longer an elevated 
risk of fatal acute myocardial infarction.66 
Interestingly, a Finnish study conducted as 
early as in the late 1980s observed an increased 
CV mortality over a 10-year follow-up in 500 
men but not in 500 women with established 
RA.192 Regarding CV case fatality, a recent 
prospective analysis of 480 RA patients from 
2009-2011 revealed a case fatality rate aft er 
the fi rst CV event of only 6.9%, which was, 
in the light of a literature review comprising 
six studies, considerably lower than in studies 
with observation periods from the years 
1955-2006.193 Th at study may have been, 
however, statistically underpowered, since 
only 29 patients experienced a fi rst CV event, 
of which no more than two were fatal.
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2.2.3  RA medications and risk for 
CV morbidity and mortality
Accumulating data demonstrate that 
antirheumatic therapy eff ectively reduces 
several markers of CV risk.130,135,143 Regarding 
clinical CV outcomes, better control of 
systemic infl ammation, especially during 
the fi rst few years of RA, may confer CV and 
survival benefi ts.128 Both exposure to each RA 
fl are and cumulative disease activity seem to 
lead to increased risk for CV events.194 Th e 
importance of achieving sustained remission 
in RA is highlighted also by observation of 
higher NT-proBNP levels, higher brachial and 
central systolic blood pressure, and indicators 
of arterial stiff ness among patients with 
active RA than among patients in remission 
and controls.195 Furthermore, the notion that 
early uncontrolled infl ammation predicts 
progression of arterial stiff ness in later 
stages of RA emphasizes the importance of 
introducing aggressive antirheumatic therapy 
as early in the disease course as possible.196
Emerging epidemiologic evidence among 
RA patients indicates that methotrexate may 
reduce CV risk.197 When the results of the 
most relevant studies are combined, reduction 
in clinical CV events is approximately 20%.198 
In one prospective study of 1,240 RA patients, 
CV mortality was reduced by as much as 70% 
and overall mortality by 60% in patients ever 
vs. those never treated with methotrexate.199 
A more recent 25-year prospective study of 
more than 5,000 RA patients revealed similar 
results, that is, that methotrexate use was 
associated with a 70% reduction in overall 
mortality.200 Not all studies, however, have 
reported methotrexate to be associated with 
decreased rates of CV events or deaths.201,202 
To date, no randomized controlled trial 
has directly evaluated whether methotrexate 
reduces CV event rates in RA or non-RA 
patients.203 An initial trial on the use of 
methotrexate among 50 non-RA patients 
with CHF showed no diff erences between 
the methotrexate and placebo groups for the 
primary end-point: the 6-minute walk-test 
distance.204 Currently, a large, randomized, 
double-blind, placebo-controlled trial known 
as the CV Infl ammation Reduction Trial 
is testing methotrexate (15-20mg/week) as 
cardioprotective therapy in 7,000 non-RA 
patients with stable CHD and diabetes 
mellitus or metabolic syndrome.205 Th is 
study will, if methotrexate does improve 
CV outcomes, not only strongly support the 
infl ammatory hypothesis of atherothrombosis 
but also provide innovative directions for CV 
disease management. 
TNF blockers can reduce the likelihood 
of CV outcomes.206 In a recent German 
study of 8,908 RA patients, TNF-inhibitor 
and rituximab users had signifi cantly lower 
mortality rates than did methotrexate users.207 
A retrospective cohort study of 2,101 RA 
patients demonstrated that, when compared 
to patients using non-biologic DMARDs 
other than methotrexate, the use of TNF 
inhibitors was associated with a decreased 
risk for CHD (hazard ratio [HR] 0.45 [95% CI 
0.21-0.96]).202 A similar but not statistically 
signifi cant decrease was observable for 
methotrexate (HR 0.54 [95% CI 0.27-1.09]).202 
In one Swedish study, 7,704 RA patients 
treated with TNF inhibitors were at lower 
risk for acute coronary syndrome than were 
those never exposed to biologics (HR 0.8, 
95% CI 0.7 to 0.95), but at higher risk than 
was the general population (HR 1.6, 95% CI 
1.4 to 1.9).182 In another Swedish cohort of 
6,000 early RA patients, patients on anti-TNF 
therapy had, however, a similar risk for acute 
coronary syndrome during the fi rst years of 
RA as did those never undergoing anti-TNF 
therapy.208
Hydroxychloroquine may have 
cardioprotective properties through its 
benefi cial eff ects on fasting lipid profi les.209,210 
In an American RA cohort predominantly 
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white, male, and elderly, hydroxychloroquine 
use for at least three months was associated 
with improved lipid profi les irrespective of 
disease activity and statin use.211 Th e authors 
suggested that, given the safety and low cost 
of hydroxychloroquine, its continuous use 
as part of an RA treatment regimen might 
be a reasonable means of reducing CV risk. 
Initial data suggest that hydroxychloroquine 
may also reduce platelet aggregation when 
administered alone or when combined with 
aspirin.212
Not all medications for RA are favorable 
for the CV system. A recent meta-analysis 
indicated that although NSAIDs have 
slightly diff erent CV risk profi les, none 
of them is completely safe in CV terms.213 
Unfavorable side eff ects can include 
hypertension, heart failure, and weakening 
of the antithrombotic eff ect of aspirin.214 
As promoters of thrombotic CV events, 
cyclo-oxygenase-2 selective inhibitors and 
traditional NSAIDs do not seem to diff er.215 
Cytotoxic immunosuppressive agents may 
also aggravate CV risk.216 
Glucocorticoids are well known 
for their unfavorable eff ects on CV risk; 
among their many important CV side-
eff ects are hypertension, insulin resistance, 
hypercholesterolemia, and weight gain.80 
Accumulating epidemiological data suggest 
a positive association between glucocorticoid 
use and CV events and mortality. A recent 
study on this topic demonstrated a dose-
dependent increase in mortality rates 
associated with glucocorticoids among 779 
RA patients.217 Furthermore, they found a 
minimum daily prednisone dose threshold 
of 8 to 15 mg associated with an increase in 
mortality.217 Another recent study including 
over 8,000 RA cases observed for more than 
50,000 person-years suggested that both 
current dosage and cumulative exposure to 
glucocorticoids associate with risk for CV 
events.218 A 10-year follow-up of a 2-year 
randomized trial involving prednisolone 7.5 
mg/day in addition to DMARDs compared 
to DMARD therapy without prednisolone 
found, however, a similar incidence of 
ischemic coronary artery events but a higher 
incidence of ischemic cerebrovascular events 
in those assigned to prednisolone compared 
to DMARDs alone.219
Despite epidemiological fi ndings 
regarding the deleterious eff ects of 
glucocorticoids on CV outcomes,207,217,220 the 
extent to which confounding by indication is 
refl ected in these results remains unclear.221 
In theory, glucocorticoids may even have 
positive CV eff ects in RA populations via 
attenuation of infl ammation.221,222 In fact, 
a recent Dutch study on 353 RA patients 
addressing this question reported that even 
though recent, current, and cumulative 
exposure to glucocorticoids associated with 
incident CV disease, adjustment for DAS28 
and the Health Assessment Questionnaire 
(HAQ) – Disability Index negated this 
association, thus refl ecting channeling 
bias.222 Th e German study on 8,909 RA 
patients, however, reported that treatment 
with glucocorticoids (dosage >5 mg/day) 
was signifi cantly associated with increased 
all-cause mortality in a dose-dependent 
manner, and this study reduced the impact 
of channeling bias by taking into account 
disease activity and functional capacity as 
time-varying covariates.207
In sum, emerging data indicate that tight 
disease control is benefi cial for RA patients 
also in CV terms. Furthermore, methotrexate 
and TNF inhibitors may improve CV 
outcomes, whereas most evidence suggests 
that glucocorticoids and NSAIDs have mainly 
detrimental CV eff ects. Until results from 
well-designed, randomized controlled trials 
are available, however, it is impossible to fully 
determine the CV risks and benefi ts of these 
agents.
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2.2.4  Assessment and treatment of 
CV comorbidities in RA
As the increased CV burden related to RA 
has become widely acknowledged among 
rheumatologists, the question arises how to 
deal with this risk in daily practice. Because 
of the mechanisms underlying CV risk 
related to RA, suppression of disease activity 
and systemic infl ammation are crucial for 
CV disease prevention. Equally important is 
the treatment of traditional CV risk factors. 
Evidence suggests that statins provide a 
cholesterol-reducing eff ect in infl ammatory 
joint diseases similar to that in healthy 
controls,223,224 and the statin dosage to obtain 
recommended lipid targets is not aff ected 
by the level of systemic infl ammation.225 
Interestingly, statins may also have anti-
infl ammatory and immunomodulatory 
properties that could attenuate RA-related 
infl ammation and disease activity.226,227 Statins 
as primary prevention in RA are associated 
with lower risk for CV events and mortality;228 
statin discontinuation is associated with 
higher risk of CV death.229 Th is emphasizes 
the importance of compliance with statin 
therapy also among RA patients. Some studies 
have shown that exercise and treatment 
with angiotensin-converting enzyme (ACE) 
inhibitors confer positive CV eff ects in RA.230 
For smokers with RA, smoking cessation 
is undoubtedly very important in CV risk 
reduction.231
Th e interpretation of lipid levels in RA is 
not a straightforward process. Th e association 
between total cholesterol and risk for CV 
events is weaker in RA than in the general 
population,232 since infl ammation distorts the 
relationship between lipid levels and CV risk. 
One American study of a predominantly male 
RA cohort comprising 37,000 patients showed 
no evident association between CHD and 
LDL cholesterol, but an inverse association 
between CHD and HDL cholesterol.233 When 
evaluating CV risk in RA, total cholesterol/
HDL ratio may therefore give a better estimate 
of CV risk than would total cholesterol 
alone.234 Moreover, it is advisable to reassess 
cholesterol levels aft er suppression of 
infl ammation and only then decide whether 
to start lipid-lowering therapy, because aft er 
the initiation of eff ective antirheumatic 
therapy, lipid levels usually increase.91 
Th e need for preventive CV 
pharmacotherapy in infl ammatory joint 
diseases is high,235 but alarmingly, RA patients 
are less likely to be prescribed CV medications 
than are non-RA patients both for primary 
and for secondary prevention.236,237 Moreover, 
RA patients meeting guideline-based 
hypertension criteria are less likely to receive 
a diagnosis of hypertension in primary 
care than are those without RA, despite 
more frequent visits.238 Th ese fi ndings are 
worrisome not only because of the elevated 
risk for CV events, but also because long-
term outcomes aft er a CV event may be 
poorer among RA patients.174 In the future, 
closer collaboration between rheumatologists, 
cardiologists, and primary-care physicians, 
and nurse-led programs may aid in better 
prediction and management of CV risk in 
RA.239,240 Th is may involve establishment of 
preventive cardio-rheuma clinics, two of 
which already exist in Oslo, Norway, and in 
Rochester, Minnesota, USA.235,239
Specifi c guidelines have been developed 
to enhance the management of CV risk in RA. 
In 2010, EULAR provided evidence-based 
recommendations for CV risk management 
for RA and other forms of infl ammatory 
arthritis.231 Th ey emphasized aggressive 
control of RA-related infl ammation, and 
smoking cessation, and refraining from 
use of high doses of glucocorticoids. CV 
risk management, including treatment of 
hyperlipidemia and hypertension, was to 
be according to local guidelines. An annual 
CV risk assessment was recommended, and 
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additional risk assessment if antirheumatic 
treatment changed. 
Th e Finnish Current Care Guideline 
for RA has a viewpoint toward CV risk 
quite similar to that of the EULAR 
recommendations.241 It states that CV risk 
assessment should be a part of routine 
general assessment in RA. In contrast to 
the EULAR recommendations, the Finnish 
guidelines suggest that treatment goals 
for hyperlipidemia should be the same as 
for other groups at high CV risk. What 
remains unclear, however, is how oft en 
these guidelines are implemented in clinical 
practice. Furthermore, randomized controlled 
trials are warranted to evaluate whether, for 
preventing CV events in RA, stricter-than 
normal blood pressure and lipid treatment 
targets are superior to current practice.230
It is not yet clear what would be the best 
method in RA to detect CV risk. Many of the 
established CV risk-prediction tools such as 
the Systematic COronary Risk Evaluation 
(SCORE), Reynolds risk score, and the 
Framingham risk score may underestimate 
risk for CV disease in RA, because they 
take into account only traditional CV 
risk factors, not those related to systemic 
infl ammation or autoimmunity.242,243 Th is 
is especially true among seropositive and 
elderly patients,242 and among patients 
categorized as in low or medium CV risk 
groups in these risk-prediction models.244 
Validated and more discriminating CV risk 
assessment tools for this purpose are thus 
vital. Aiming at responding to this need, A 
TransAtlantic Cardiovascular risk Calculator 
for Rheumatoid Arthritis (ATACC-RA) 
consortium, including 13 rheumatology 
centers from 10 countries, is currently 
developing an RA-specifi c algorithm for CV 
risk estimation.245
Th e EULAR recommendations suggest 
a multiplication factor of 1.5 to be added to 
the CV risk estimate measured by SCORE 
or by the Framingham Risk Score for those 
who fulfi ll two of the following criteria: 1) 
RA disease duration >10 years, 2) presence 
of RF or ACPA, and 3) presence of severe 
extra-articular manifestations. Even aft er 
applying this multiplication factor, however, 
the SCORE risk factor equation may still not 
estimate CV risk in RA accurately.246,247 Such 
a risk underestimation may at least in part be 
explained by the fact that increased CV risk 
is confi ned not only to patients with RA for 
over ten years, but also to early RA patients.169 
Carotid ultrasonography together with risk 
prediction equations may improve CV-risk 
stratifi cation.248 
2.3  Autoimmune thyroiditis and 
hypothyroidism
Autoimmune diathesis, a theory suggesting 
a tendency for autoimmune diseases to 
co-exist within individuals in excess of levels 
expected by chance, is generally accepted in 
clinical work.5 Indeed, thyroid abnormalities 
in RA are most commonly autoimmune, 
and may present with hypo-, eu-, or 
hyperthyroidism.249 
Epidemiological studies since the 1960s 
have shown that RA and chronic autoimmune 
thyroiditis (i.e. Hashimoto’s thyroiditis), a 
common cause of hypothyroidism, co-occur 
more frequently than expected.4,250-253 For 
instance, Shiroky and coworkers studied 
91 Canadian women with RA in the early 
1990s and found that thyroid dysfunction 
was three times as common in this RA 
cohort as in patients of similar demographic 
characteristics with non-infl ammatory 
rheumatic diseases.254 Of note, this excess 
risk was entirely due to hypothyroidism 
or confi rmed Hashimoto’s thyroiditis.254 
Prevalence estimates for autoimmune 
thyroiditis in RA vary substantially between 
studies from various countries and with 
diff ering methodologies. In a recently 
conducted literature review, estimates for the 
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prevalence of autoimmune thyroid disease in 
RA ranged from 0.5% to 27% across studies 
from diff ering areas.255
Th e etiology underlying co-occurrence 
of RA and autoimmune thyroiditis has 
been investigated, for example, with 
respect to interrelating genes251,256 and 
autoantibodies.257 Common susceptibility 
alleles to these diseases include PTPN22 
and HLA-DR.249,250,258 Initial data imply that 
CTLA4 gene polymorphisms may also play 
a role.259 Moreover, fetal microchimerism has 
been linked to the pathobiology of both RA 
and Hashimoto’s thyroiditis.260 
Investigating the coexistence of 
autoimmune diseases typically involves 
patients with an index disease such as 
RA; assessment of comorbid autoimmune 
disorders occurs when the index disease 
is fully established.250 Initial autoimmune 
processes in RA may, however, activate 
years before its clinical onset.123 Th is may 
thus already be aff ecting the development 
of autoimmune thyroiditis and its clinical 
manifestation, hypothyroidism, even in 
preclinical RA phases. To our knowledge, 
studies on this topic are lacking. 
2.4  Psychiatric disorders
Depressive symptoms may be up to 2 to 3 
times as common in RA as in the general 
population.2,3 A recent population-based 
study on more than 3,300 infl ammatory-
arthritis patients showed, during a median 
follow-up of 2.8 years from disease onset, an 
increased risk for developing both anxiety 
and depressive disorders (HRs 1.4 and 
1.4, respectively).261 Depression in RA is 
associated with physical disability, fatigue, 
disease activity, and, above all, the experience 
of chronic pain.2 Emerging evidence indicates 
that bidirectional interactions exist between 
mood disorders and infl ammation, and this 
might also in part explain the high prevalence 
of depression in RA.262 
Prevalence estimates for depression in 
RA are highly variable across studies, partly 
due to diff erences in methods for identifying 
depression and partly due to variation in study 
quality.263 According to a recent systematic 
review and a meta-analysis evaluating 72 
studies of RA, the pooled prevalence (95% 
CI) of a major depressive disorder was 16.8% 
(10.0-24.0%) according to the Diagnostic and 
Statistical Manual (DSM) criteria, and 38.8% 
(34.0-43.0%) according to the Patient Health 
Questionnaire 9 (PHQ-9) depression scale.263 
Schizophrenia, on the other hand, seems 
to be negatively associated with RA. In a 
Taiwanese registry study of more than 10,000 
schizophrenia patients, when compared with 
100,000 age-matched controls, the OR for 
RA was 0.52 (95% CI 0.35-0.76).264 Similar 
fi ndings appear in several other studies.265,266 
Some studies have tried to investigate whether 
genetics explains this negative relationship, 
with no major breakthroughs.267 Moreover, 
it has been suggested that autoimmune 
mechanisms play a role in the development of 
schizophrenia.268
2.5  Comorbidities and work 
disability
An issue investigated surprisingly little is 
whether the high prevalence of comorbidities 
contributes to the development of WD in 
RA. A Dutch study on 508 RA patients who 
were using TNF inhibitors demonstrated 
that having comorbidities is associated with 
stopping working.269 In one small case-
control study among patients with established 
RA, the odds ratio for permanent WD in 
patients with any comorbidity vs. without 
comorbidities was as high as 7.54.9 
Depressive symptoms and anxiety have 
associated with WD in some relatively small 
RA populations.10-12 In one German study on 
356 patients with an infl ammatory rheumatic 
disease, a psychiatric comorbidity as assessed 
by the PHQ was an independent predictor 
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of WD.10 More specifi cally, a comorbid 
psychiatric disorder raised WD from 25% 
to 50% in severe infl ammatory rheumatic 
disease and from 5% to 17% in mild disease, 
rheumatic-disease severity being assessed 
by the treating physician on a 5-step rating 
scale. In addition, the severity of depression 
was an independent predictor of WD.10 In 
one Norwegian study comprising 474 RA 
patients aged 18 to 45, WD pension risk 
was associated with worse mental health as 
assessed by patient-reported Short Form (36) 
Health Survey.53
No literature yet exists on the role of CV 
diseases as leading to WD in RA cohorts. 
A Dutch prospective study in 1998-2008 
assessed the eff ect of CV comorbidities on 
work participation in patients with rheumatic 
diseases in a cohort of 12,140 employees from 
45 companies and organizations. Th ere, a self-
reported CV comorbidity did not additively 
aff ect the length and frequency of sick leave 
episodes or long-term WD among patients 
with a self-reported rheumatic disease, 
although both CV and rheumatic diseases 
elevated sick leave and WD rates separately.270 
However, because rheumatic diseases other 
than RA such as osteoarthritis, fi bromyalgia, 
and gout constituted the majority of the 
rheumatic diagnoses in the study, the 
generalizability of the results to RA patients is 
limited.
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Aims of the study
Th e main aim of this work was to elucidate the epidemiology of comorbidities in early RA, with 
emphasis on CV disease. Specifi c aims were to discover:
1. Th e prevalence of CHD, chronic hypertension, and CHF at RA diagnosis, and to compare 
this with fi gures for an age- and sex-specifi c general population. 
2. Th e prevalence of hypothyroidism at RA diagnosis, and to compare it with that of the 
general population. 
3. Th e contribution of psychiatric and CV comorbidities to long-term WD in recent-onset 
RA, and to compare rates of WD resulting from these diseases with those of the general 
population. 
4. CV mortality in the early years of RA, to compare it to the general populations’, and to 
evaluate the impact of RA medications on CV mortality.
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3  Background
Th e data for this work came solely from 
nationwide Finnish registers and statistics, 
e.g. the register of special reimbursements 
for medicine expenses, the pension registers 
maintained by Kela (Th e Social Insurance 
Institution of Finland) and the Finnish 
Centre for Pensions, the archive of death 
certifi cates, the statistics on causes of death, 
and the prescription register. Th ese registers 
are maintained primarily for administrative 
needs but also serve research purposes. As 
the data in the registers are coded according 
to the personal identifi cation number of every 
permanent Finnish resident, it was possible to 
combine all of each person’s data. 
3.1  Register of special 
reimbursements for medicine 
expenses
All permanent residents of Finland are 
covered under general sickness insurance, 
which includes reimbursements for the 
costs of outpatient prescription medicines 
for the treatment of illness. Th ese medicine 
costs are reimbursed by Kela at three rates 
of reimbursement: the basic, the lower, and 
higher special reimbursements. Th e basic 
reimbursement is granted from Kela without 
a doctor’s certifi cate. Between 2000 and 
2007, this covered 42 to 50% of the price of 
the medicinal product.271 Lower and higher 
special reimbursements can be applied for 
the pharmacotherapy of certain chronic and 
severe diseases such as CHD, CHF, RA, and 
diabetes with an examination-based doctor’s 
certifi cate. 
To qualify for special reimbursement, 
the patient must fulfi ll Kela’s set of predefi ned 
medical criteria for his/hers condition. 
Th e criteria for special reimbursement are 
oft en not the same as the medical criteria 
for starting medication. According to good 
clinical practice, if the patient fulfi lls the 
criteria for special reimbursement, the 
treating physician routinely fi lls in the 
required certifi cate (Medical Certifi cate B). 
For many diseases, the medical certifi cate 
must be issued either in a specialist-level 
health care unit or by a specialist, but for 
some common diseases such as hypertension 
or hypothyroidism, any physician can 
complete the certifi cate. Th e certifi cate must 
describe the signs, symptoms, and course of 
the disease, diagnostic procedures, and the 
relevant ICD-10 code(s). It must also include 
a plan for disease monitoring and treatment. 
It is possible to apply special reimbursements 
for more than one disease with only one 
certifi cate. Th e Medical Certifi cate B costs the 
patient typically 30 euros when received from 
public health care,272 and from 60 to 140 euros 
from private health care.273
Before granting of the special 
reimbursement, the medical certifi cate is 
submitted to Kela, where a medical examiner 
physician or pharmacist at Kela checks and 
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approves it. Th e special reimbursements 
are granted independently of the patient’s 
socioeconomic status or place of residence. 
Between 2000 and 2007, the lower special 
reimbursement covered 72 to 75% of the 
price of the medicine, and the higher special 
reimbursement covered 100%.271 To qualify 
for reimbursement, the medicine must be 
purchased in the most economical package 
size for a maximum of 3 months’ use. 
Special reimbursement decisions are 
recorded in a nationwide register by date of 
reimbursement decision and a set of Kela 
codes for the diseases qualifying for special 
reimbursement. From 2000 onwards, this has 
also included the respective ICD-10-codes for 
diagnoses of chronic diseases. 
3.1.1  Rheumatoid arthritis
In order to establish entitlement to 
special reimbursement for antirheumatic 
medications, a patient must fi le an 
examination-based medical certifi cate 
issued by a rheumatologist or physician with 
experience of rheumatology. Th e certifi cate 
must describe the proper diagnostic 
procedures and ICD-10 code (M05 for 
RF-positive RA and M06 for RF-negative RA) 
as well as a treatment plan in accordance with 
good clinical practice. Th e reimbursement 
system covers any antirheumatic medication 
necessary to control the disease activity 
of each patient, also during remission. 
Practically all Finnish patients with 
antirheumatic medications are eligible for the 
special reimbursement from the early phases 
of the disease, because it is a routine policy 
in the rheumatology clinics of Finland to 
complete this certifi cate at the diagnosis of an 
infl ammatory rheumatic disease. 
3.1.2  Cardiovascular disease and its 
risk factors
For many chronic CV diseases, a diagnosis 
entitles patients to special reimbursement 
for medication costs. Regarding CHD, the 
doctor’s certifi cate sent to Kela is usually 
completed in a clinic of cardiology or 
internal medicine. It must describe the signs, 
symptoms, and diagnostic procedures for 
the patient with chronic CHD. For example, 
patients who have suff ered a myocardial 
infarction, undergone a percutaneous 
coronary intervention or coronary artery 
bypass graft ing, or patients with chronic 
angina pectoris whose rest or exercise 
electrocardiogram shows signs of CHD are 
entitled to the special reimbursement. Th e 
medical certifi cate must also include one of 
the ICD-10 codes: I20–I22, I24.0, or I25. 
Chronic hypertension is the most 
common disease entitling patients to special 
reimbursement of medications in Finland, 
covering more than 10% of the population. 
To establish this particular entitlement, 
the patient must have received treatment 
for at least 6 months with antihypertensive 
agents. Th e medical certifi cate must include 
an ICD-10 code of I10–I13, I15, or I27.0 
and describe either clearly elevated blood 
pressures, additional CV risk factors or the 
presence of an end-organ complication. Th us, 
patients with only mild hypertension are 
ineligible for reimbursement. 
Similarly, patients with CHF are entitled 
to special reimbursement by an ICD-10 
code of I11.0, I13, I50, or I97.1. Chronic 
cardiac arrhythmias entitle patients to special 
reimbursement of medications by ICD-10 
codes I47 to I49. For diabetes, the special 
reimbursement is granted if the medical 
certifi cate shows that either the 1) fasting 
plasma glucose is >7.0 or fasting blood 
glucose >6.1 mmol/l, 2) plasma/blood glucose 
is >11.1/10.0 mmol/l in one measurement, 
3) glucose tolerance test 2-hour plasma/
blood glucose is >11.1/10.0 mmol/l, or 4) 
HbA1c is >48 mmol/l. Th is certifi cate must 
include one of the ICD-10 codes E10-E14, or 
E89.1, that includes both type I and type II 
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diabetes. Patients with chronic CHD-related 
dyslipidemia were, until 2011, entitled to a 
separate special reimbursement for lipid-
lowering agents. Nowadays, treatment 
of dyslipidemia is included in the special 
reimbursement for CHD medications.
3.1.3  Hypothyroidism
Patients with clinical hypothyroidism 
are entitled to special reimbursement for 
levothyroxine substitution. A medical 
certifi cate describing the etiology, the clinical 
picture of hypothyroidism, and the levels of 
thyroid-stimulating hormone and thyroid 
hormone T4 is sent to Kela as an enclosure 
in the application for special reimbursement. 
Because of the high prevalence of 
hypothyroidism, this certifi cate can be issued 
not only by an endocrinologist but also by a 
general practitioner.
Th e special reimbursement for 
levothyroxine is granted for patients under 
ICD-10 codes C73, E03, and E89.0. Th us, not 
only chronic autoimmune thyroiditis , but also 
other, rarer forms of primary hypothyroidism 
(inadequate function of the thyroid gland 
itself) qualify for the special reimbursement, 
including postprocedural hypothyroidism, 
hypothyroidism aft er radioiodine therapy, 
and hypothyroidism caused by medications 
or malignant neoplasms of the thyroid gland. 
Iodine-defi ciency-related hypothyroidism 
and subclinical hypothyroidism, on the 
other hand, do not qualify for special 
reimbursement. Central hypothyroidism is 
covered under the special reimbursement for 
hypopituitarism and is thus excluded from 
our data. Because levothyroxine is such a 
low-priced medicine (in 2007, a 100-tablet 
package of either 25 or 100 μg strength cost 
4.97 euros274), not all hypothyroid patients 
on levothyroxine may apply for the special 
reimbursement. Th is is likely to result in a low 
coverage of hypothyroid patients both among 
the patients with future RA and the general 
population.
3.2  Pension registers
Th e statutory pension system in Finland 
consists of two main parts –  an earnings-
related pension and a residence-based 
national pension. Th e earnings-related 
pension, managed by various earnings-
related pension providers that belong to the 
Finnish Centre for Pensions, covers the entire 
workforce, including the self-employed. Th e 
national pension provides minimum security 
and income for those who have an insuffi  cient 
earnings-related pension. Th e national 
pension is managed by Kela.275
Disability pensions are granted for 
permanent Finnish residents of working age 
who have a long-term disease that prevents 
them from working. At fi rst, employees are 
paid an allowance for a maximum of 300 days 
of illness. Disability pensions can be applied 
for at Kela or the Finnish Centre for Pensions 
with an examination-based doctor’s certifi cate 
aft er 150 weekdays of sickness allowance. 
Usually, when the allowance period ends, the 
work-disabled person will receive a temporary 
disability pension entitled a rehabilitation 
allowance in Finnish legislation. During the 
rehabilitation allowance, the pension recipient 
receives rehabilitation in order to restore work 
capacity from either the earnings-related or 
the national pension scheme.
Later, if the medical treatment and 
vocational rehabilitation cannot restore the 
patient’s ability to earn a reasonable living, a 
permanent disability pension follows. If the 
pension recipient has an illness, defect, or 
injury that causes a 60% reduction in work 
capacity, a full-time permanent disability 
pension can be issued. If work capacity is 
reduced by 40% but by less than 60%, a 
partial disability pension is issued. Data 
on sick leaves, rehabilitation allowances, 
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and disability pensions are gathered in the 
pension registers maintained by Kela and the 
Finnish Centre for Pensions.
3.3  Statistics Finland’s archive 
of death certificates and 
annual statistics on causes 
of death
When a person dies, the treating physician 
writes a death certifi cate which includes the 
underlying cause of death, causes leading 
to death, the immediate cause of death, a 
possibility to enter contributory causes of 
death, a short case-history of the deceased, 
and a description of the circumstances 
of death.276 Causes of death are classifi ed 
according to the ICD-10 code system. Causes 
of death are oft en based on the diseases 
known before death, but in some cases, 
a post-mortem investigation is necessary 
because the cause of death is unknown, or 
unexpected, or if the deceased was not under 
a doctor’s care during his/her last illness. 
In 2008, a medical autopsy was performed 
for 7.0% and a forensic autopsy for 24.0% of 
those deceased.277
Statistics Finland maintains an archive 
of death certifi cates that includes death 
certifi cates from 1936 onwards.278 From 
this archive, information on mortality and 
causes of death can be obtained for scientifi c 
purposes with written permission from 
Statistics Finland. 
Statistics Finland also produces annual 
statistics on causes of death in the entire 
Finnish population, covering all permanent 
Finnish residents who have died in Finland 
or abroad during the calendar year. Data 
on causes of death for these statistics are 
compilations of data in the death certifi cates 
according to underlying cause of death. Th e 
statistics contain data on mortality according 
to cause of death (54-group classifi cation of 
ICD-10 codes), age, and sex.278
3.4  Prescription register
Kela maintains a prescription register 
recording outpatient medicine purchases of 
reimbursable medicines from pharmacies. It 
was established in 1994, and serves primarily 
administrative purposes. Medicine purchases 
are fi led according to the Anatomical 
Th erapeutic Chemical (ATC) code,279 and 
date of purchase and number of purchased 
packages are retrievable. Th e prescriptions are 
valid for 1 year from the day on which they 
were prescribed, but Finnish reimbursement 
regulations restrict the maximum number 
of packages supplied per redemption to 
cover only a 3-month period. Intravenous 
medicines such as infl iximab are reimbursed 
by hospitals and outpatient clinics, and 
their use is therefore not recorded in this 
register. Further, the register does not include 
over-the-counter medicines. If the patient 
presents his/hers Kela card when purchasing 
medicines, the reimbursement can oft en 
be credited directly at the pharmacy. Th e 
reimbursement can also be claimed aft erwards 
from Kela within six months of the purchase. 
Th e coverage of prescription medicine 
purchases in the register is approximately 75 
to 95%, and varies according to calendar year 
and medicinal product.280 
4  Patient cohorts
Th e case identifi cation method of this 
study relied on the special reimbursement 
decisions for RA medications. We identifi ed 
all the adult RA patients under ICD-10 
codes M05 and M06 who were granted the 
special reimbursement of medications for RA 
from the register of special reimbursement 
decisions, using the date of the reimbursement 
decision as the RA index date (Figure 5). 
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5  Outcomes
5.1  Comorbidities at diagnosis 
of RA
Data on comorbidities were retrievable 
from the register of special reimbursement 
decisions. Data on existence of CHD, chronic 
hypertension, and hypothyroidism at the RA 
index date were collected by requiring that the 
medicine reimbursement decision antedates 
the medicine reimbursement decision for 
RA (Studies I and II). We also present similar 
unpublished data on CHF, other CV diseases, 
and CV risk factors. 
5.2  Work disability caused by 
comorbidities
From the pension registers, we obtained data 
on any kind of pension in the RA cohort 
as well as in the entire Finnish population 
up until December 31, 2008. In analyses 
of these data, we included all incident 
permanent disability pensions occurring aft er 
the diagnosis of RA and those temporary 
disability pensions that had continued for 
at least one year at the end of follow-up. 
Hereaft er, these disability pensions are 
designated as WD. Th e patients were followed 
up until the beginning of a disability pension, 
of normal retirement, until death, or until the 
end of 2008. From the same registers came 
data on periods of sickness allowance longer 
than ten days. Compensation of lost income 
is not granted for sick leaves shorter than or 
equal to ten days, and data on those short sick 
leaves were thus unavailable.
Th e primary outcomes for Study III 
were WD-causing CV disease and psychiatric 
disorders. Th e leading cause for the disability 
pension of each patient was identifi ed by 
the fi rst (i.e. the most important) diagnostic 
ICD-10 code in the pension registers. CV 
diseases were identifi ed by the codes I00–
I99 and RA by M05/M06. We identifi ed 
psychiatric disorders by ICD-10 codes F20–
F69, including schizophrenia; schizotypal 
and delusional disorders; mood disorders; 
neurotic, stress-related, and somatoform 
Figure 5. Case identifi cation protocol for Studies I-IV. 
 
Studies I and II
7,209 incident RA cases
Study III
7,831 incident RA cases
Study IV
14,878 incident RA cases
Excluded if retired 
or >64 years of age
Eligibility for special 
reimbursement for 
antirheumatic medication 
(M05 or M06)
Index date
1 Jan 2004─31 Dec 2007
≥20 years of age
Index date
1 Jan 2000─31 Dec 2007
≥18 years of age
Finnish population
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disorders; behavioral syndromes associated 
with physiological disturbances and physical 
factors; and disorders of adult personality 
and behavior. Th is composite outcome will 
be referred to as “psychiatric disorders” or 
“psychiatric comorbidities.” 
5.3 Cardiovascular mortality
We obtained the underlying cause of death 
for each RA patient from the archive of death 
certifi cates maintained by Statistics Finland 
(Study IV). Th e validity of this register, 
particularly regarding CV causes, has been 
demonstrable.276,281 CV disease was identifi ed 
as the underlying cause of death by ICD-10 
codes I00 to I99. Th e CV disease-specifi c 
death rates in the age- and sex-specifi c general 
population came from the annual statistics on 
causes of death (Statistics Finland). Patients 
were followed up until death or the end of 
December 2008, whichever occurred fi rst. 
We assessed the eff ect of several factors 
on CV mortality, including RA medications 
and comorbidities. Th e comorbidities 
comprised cardiac diseases (CHD, CHF, 
or chronic arrhythmias with or without 
hypertension), hypertension without cardiac 
disease, diabetes, asthma, chronic obstructive 
pulmonary disease (COPD), and prior 
malignancies. We were unable to distinguish 
between patients who had cardiac disease 
with or without hypertension, because 
the medications for these diseases overlap 
substantially, and a patient may have both 
conditions but be eligible only for the special 
reimbursement for cardiac disease. 
From the prescription register 
maintained by Kela, we extracted data on 
the use of RA and CV disease medications. 
Th e specifi c RA medications included 
methotrexate, hydroxychloroquine, 
sulfasalazine, glucocorticoids, and 
subcutaneous TNF inhibitors. Th e register 
contains no information on intravenously 
administered biologic agents. CV disease 
medications were categorized by ATC code 
subgroups. For each purchase, Kela provides 
reimbursement for medications for only 
three-month use. Th erefore, we assumed 
that one medicine purchase corresponds to 
three months of medication use. In assessing 
the total duration of use for each RA or 
CV medication, the number of medicine 
purchases was multiplied by a three-month 
period, and the medication-use duration was 
determined as a percentage of patient-years. 
Because of the frequency of combination 
therapies, this method would have yielded 
falsely high results for evaluating the duration 
of treatment with any RA medication (data in 
Figure 19). For this reason, we estimated the 
duration of any RA medication by calculating 
the remainder of the last and fi rst medicine 
purchases and adding a three-month period.
6  Ethical considerations
We used only offi  cially archived register data, 
which are available without any patient-
specifi c consent. Permission for use of these 
data came from the administrator of each 
register, i.e., Kela, Statistics Finland, and 
the Finnish Centre for Pensions. Every 
patient was given an identifi cation number, 
according to which the data were analyzed 
anonymously. 
7  Statistical analysis
In analysis of the use of RA medications 
and number of WD days, the statistical 
signifi cance of diff erences between groups 
was evaluated by bootstrap type analysis 
of variance (ANOVA) or co-variance 
(ANCOVA) with appropriate contrast; 
95% CIs were obtained by bias-corrected 
bootstrapping (5000 replications). 
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For estimation of cumulative incidence 
functions and adjusted sub-hazard ratios 
(sHRs), we used the Fine and Gray 
competing-risks regression model (Studies III 
and IV). In general, competing-risks analyses 
are suitable for settings in which subjects are 
at risk for more than one mutually exclusive 
event such as competing causes of death.282 
For estimating cumulative incidences of 
WD (Study III), competing risks comprised 
WD due to causes other than the disease of 
interest and death before age 65. Similarly, for 
estimating the cumulative incidence of CV 
death (Study IV), competing risks comprised 
causes of death other than CV disease.
In order to compare the rates of primary 
outcomes to the general population, we 
used Poisson regression models and yielded 
standardized rate ratios (SRRs) with 95% CIs. 
Th e standardized mortality ratio (SMR) is the 
ratio of the number of observed deaths in a 
study population divided by the number of 
expected deaths. Expected numbers of deaths 
were calculated by multiplying patient-years 
at risk by the age- (in 5-year categories), 
sex-, and calendar-year-specifi c death rate. 
Similarly, to compare WD incidence rates 
in the RA cohort to those in the general 
population, we analyzed the standardized 
incidence ratio (SIR) based on observed 
and expected incidences of WD in the RA 
population. 
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8  Characteristics of the 
patient cohorts
Our RA populations consisted of 
predominantly female RA patients, with more 
RF-positive than RF-negative patients (Table 
5). Across the RA populations, mean age 
among women ranged from 45.5 to 56.6 years, 
and among men from 47.2 to 58.2 years.  
9  Comorbidities at diagnosis 
of RA 
In the cohort of 14,878 RA patients diagnosed 
between 2000 and 2007 in Finland, quite 
a few patients had been granted special 
reimbursements for medicine expenses due 
to some other disease before the RA diagnosis 
(Table 6). Th e most common diseases that 
had led to special reimbursements were 
hypertension, asthma and COPD, CHD, 
hypothyroidism, and diabetes mellitus. 
9.1  Coronary heart disease
Of the 7,209 RA patients, a total of 553 (7.7%) 
had a validated diagnosis of CHD at RA 
diagnosis. Of these, 287 were women (CHD 
prevalence 5.9%), and 266 were men (11.5%). 
Risk for CHD was slightly higher in the RA 
cohort than in the general population (SRR 
1.10, 95% CI 1.01 to 1.20). Th e SRR point 
estimates were similar in the RF-positive and 
RF-negative subgroups, but only that of the 
RF-negatives was statistically signifi cantly 
elevated (Table 7). 
Figure 6 illustrates the SRRs for CHD 
in subgroups by gender and age at RA onset. 
Although the SRRs were mostly no longer 
signifi cantly elevated in the age subgroups, 
patients with earlier RA onset seemed to have 
higher SRR point estimates than did patients 
who were older at RA diagnosis, especially in 
the group of patients aged 20 to 49. Absolute 
prevalence of CHD was, however, only 0.5% 
among patients aged 20 to 49, and it increased 
Results
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Table 5. Characteristics of RA cohorts in Studies I-IV
  Patients   Women   Men
  n   n (%) Age, mean 
(SD)
RF+   n (%) Age, mean 
(SD)
RF+
Studies I and II 7,209   4,887 (68) 56.6 (15.0) 64 %   2,322 (32) 58.2 (13.5) 66 %
Study III 7,831   5,552 (71) 45.5 (11.1) 60 %   2,279 (29) 47.2 (10.2) 63 %
Study IV 14,878   10,119 (68) 55.8 (15.8) 62 %   4,759 (32) 57.5 (13.9) 64 %
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Results
Table 6. Eligibilities for special reimbursements of medication expenses in the cohort of 14,878 
patients at RA diagnosis (unpublished results). 
  Percentage, %
Disease
Men 
(N=4,759)
Women 
(N=10,119)
Total 
(N=14,878)
Cardiovascular diseases 
Congestive heart failure 2.8 2.3 2.4
Hypertension 20.8 19.9 20.2
Coronary heart disease 11.6 5.9 7.7
Chronic cardiac arrhythmias 2.3 1.5 1.8
Neoplasms 
Breast cancer - 0.6 0.4
Prostate cancer 1.1 - 0.4
Neoplasms of lymphoid, haematopoietic and related tissue 0.2 0.1 0.1
Neoplasms of female genital organs - 0.2 0.1
Other malignant neoplasms 0.2 0.1 0.1
Mental and behavioural disorders 
Psychoses and other severe mental disorders 1.7 2.4 2.1
Mental retardation 0.2 0.1 0.1
Diseases of the nervous system
Multiple sclerosis 0.1 0.1 0.1
Parkinson’s disease and related movement disorders 0.4 0.3 0.3
Epilepsy 1.2 1.3 1.3
Trigeminal and glossopharyngeal neuralgia 0.1 0.1 0.1
Alzheimer’s disease 0.4 0.3 0.3
Endocrine, nutritional and metabolic diseases 
Diabetes mellitus 6.3 5.1 5.5
Hypothyroidism 1.2 6.2 4.6
Hypoparathyroidism 0.0 0.2 0.1
Pernicious anemia and other causes of vitamin B12 malabsorbtion 0.8 1.1 1.0
Hypogonadism 0.1 0.8 0.6
Chronic disorders of vitamin D metabolism 0.1 0.1 0.1
Hereditary dyslipidemias 0.2 0.1 0.1
Dyslipidemia related to coronary heart disease 5.0 2.3 3.2
Other
Glaucoma 1.9 2.6 2.4
Sarcoidosis 0.1 0.2 0.2
Asthma and other chronic obstructive pulmonary diseases 7.7 9.0 8.6
Chronic cystitis 0.2 3.1 2.2
Infl ammatory bowel diseases 0.5 0.4 0.5
Gout 1.6 0.5 0.8
Other 1.2 0.9 1.0
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steeply towards older age groups, reaching 
23% among those aged ≥80 years at RA 
diagnosis (Figure 7). We found no diff erences 
in the SRR of CHD between men: SRR (95% 
CI) 1.11 (0.98 to 1.25) and women: SRR 1.10 
(0.97 to 1.23). Th e cumulative percentage of 
CHD before RA diagnosis is shown in Figure 
8, separately for men and women aged < and 
≥70 years.
9.2  Hypertension 
A total of 1,383 (19.2%) patients had 
hypertension at RA diagnosis. Its prevalence 
was similar in men (465 cases, 20.0%) and 
women (918 cases, 18.8%). Th ere emerged 
no excess prevalence of chronic hypertension 
at RA diagnosis in the entire RA population 
or in the RF-positive subgroup. Among 
the RF-negative subgroup, however, the 
prevalence of chronic hypertension was 
slightly elevated (SRR 1.19, 95% CI 1.10–1.30) 
(Table 7). 
9.3  Other CV diseases and risk  
factors
We observed no increased prevalence of CHF, 
chronic arrhythmias, diabetes, or chronic 
dyslipidemia among newly diagnosed RA 
patients compared with that of the general 
population. Aft er stratifi cation by RF status, 
the SRRs for these comorbidities remained 
unchanged, despite slight but nonsignifi cant 
Results
Table 7. Prevalence and standardized rate ratios of CV comorbidities and risk factors in a population 
of 7,209 RA patients and in subgroups according to RF status at RA diagnosis. 
  Total (N=7,209) RF-positive (N=4,650) RF-negative (N=2,559)
Disease n SRR (95% CI) n SRR (95% CI) n SRR (95% CI)
CHD 553 1.10 (1.01 to 1.20) 355 1.08 (0.97 to 1.19) 198 1.15 (1.00 to 1.32)
CHF* 141 1.01 (0.85 to 1.19) 89 0.99 (0.79 to 1.21) 52 1.06 (0.79 to 1.39)
Chronic arrythmias* 121 1.03 (0.86 to 1.23) 69 0.90 (0.70 to 1.13) 52 1.29 (0.96 to 1.69)
Hypertension 1,383 1.05 (0.99 to 1.10) 846 0.97 (0.90 to 1.04) 537 1.19 (1.10 to 1.30)
Diabetes* 415 1.02 (0.92 to 1.12) 260 0.96 (0.85 to 1.09) 155 1.12 (0.95 to 1.31)
Dyslipidemia* 285 1.07 (0.95 to 1.21) 186 1.06 (0.91 to 1.22) 99 1.10 (0.90 to 1.34)
Abbreviations: RF, rheumatoid factor; SRR, standardised rate ratio; CI, confi dence interval; CHD, coronary heart 
disease; CHF, congestive heart failure. 
*A. M. Kerola et al. unpublished results.
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Figure 6. Standardized rate ratios (SRRs) for 
CHD at RA diagnosis by sex and age. SRRs are 
shown with 95% confi dence intervals.
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Figure 7. Percentages of RA patients with coronary heart disease (CHD) at RA diagnosis by gender 
and age at RA onset. 
elevations in the SRR point estimates of the 
RF-negative subgroup (Table 7, unpublished 
results).
9.4  Hypothyroidism 
Of the 7,209 patients with incident RA, 
a total of 350 (4.9%) had levothyroxine-
treated hypothyroidism, as identifi ed from 
the register of special reimbursements for 
medicine costs, at the time of RA diagnosis. 
Th is corresponds to a SRR of 1.51 (95% CI 
1.35 to 1.67). As in the general population, 
hypothyroidism was far more common 
among women than among men; 321 (6.6%) 
female and 29 (1.2%) male patients had both 
RA and hypothyroidism. Among women, 
the prevalence of hypothyroidism was higher 
than in the general population (SRR 1.52, 95% 
CI 1.36 to 1.69). Among men, excess risk did 
not reach statistical signifi cance (Figure 9). 
Of the RF-positive patients, 220 (4.7%) were 
treated with levothyroxine, corresponding to 
a SRR of 1.46 (95% CI 1.27 to 1.66). Among 
the RF-negative patients, the prevalence of 
hypothyroidism was similar; 130 (5.1%) were 
treated with levothyroxine substitution, the 
SRR being 1.61 (95% CI 1.34 to 1.91). 
As to the eff ect of age, we found the 
highest rate ratios of hypothyroidism among 
the youngest age groups (Figure 9), similar 
to our fi ndings regarding CHD. Among 
women, the excess prevalence was almost 2.5 
among patients aged 20 to 49, it decreased 
steadily with aging, and subsided completely 
in the oldest patients, aged >80 (Figure 9). 
Th e absolute prevalence of hypothyroidism, 
however, seemed to increase with aging, the 
highest prevalence being among patients 
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aged 70-79 years at RA onset (Figure 10). Th e 
cumulative percentage of hypothyroidism 
before RA is shown in Figure 11, separately 
for men and women aged < and ≥70 years.
We found 30 RA patients who 
had a validated diagnosis of both CHD 
and hypothyroidism at RA diagnosis, 
corresponding to 8.6% of all the 
levothyroxine-treated RA patients. 
Among RA patients without levothyroxine 
substitution, the prevalence of CHD was 
essentially similar, 7.6%.
Figure 8. Cumulative percentage of coronary heart disease before RA diagnosis in men and women at 
age < and ≥70 years (unpublished results).
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Figure 9. Standardized rate ratios (SRRs) for 
levothyroxine-treated hypothyroidism by sex 
and age. SRRs are shown with 95% confi dence 
intervals at RA diagnosis among 7,209 RA 
patients.
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Figure 10. Percentages of RA patients with levothyroxine-treated hypothyroidism (HT) at RA 
diagnosis by gender and age at RA onset.
Since the insidious symptoms of early 
RA or undiff erentiated arthritis may resemble 
those of hypothyroidism, screening for 
hypothyroidism might have occurred more 
frequently among those with oncoming RA 
than among the general population, causing a 
biased SRR for hypothyroidism. To assess the 
eff ect of this bias, the SRRs for hypothyroidism 
were calculated one year before the RA index 
date. Th ese SRRs were similar to those at RA 
diagnosis: the SRR (95% CIs) was 1.38 (1.23 
to 1.54) for the entire population, 1.39 (1.23 to 
1.56) for women, 1.30 (0.86 to 1.89) for men, 
1.35 (1.17 to 1.55) for RF-positives, and 1.44 
(1.19 to 1.73) for RF-negatives. Th e absolute 
numbers on which these estimates are based 
are shown in Table 8.
Table 8. Absolute numbers of patients with 
hypothyroidism at the rheumatoid arthritis 
(RA) index date and one year (yr) before the 
index date. 
  Cases with hypothyroidism
  At the RA index 
date
1 yr before the RA 
index date
Total 350 319
Women 321 292
Men 29 27
RF + 220 203
RF - 130 116
Results
Women 1445 1374 978 833 257
 - with HT 62 85 81 76 17
Men 571 685 554 414 98
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10  Work disability caused by 
comorbidities
During follow-up (median 4.0 years, range 
<1 to 9 years), 1,095 (14%) of the 7,831 
patients became disabled for work. Of them, 
681 (12%) were women and 414 (18%) were 
men. In 739 (67%) of the cases, the leading 
cause was RA (462 women, 277 men). 
Other musculoskeletal diseases were the 
leading causes of WD in 134 (12%) cases. 
Aft er musculoskeletal diseases, psychiatric 
disorders were the second-most frequent 
cause of disability pension (82 cases), of 
which 90% were mood disorders. In only 30 
(2.7%) cases were CV diseases the leading 
cause of WD, mainly represented by ischemic 
heart diseases and cerebrovascular diseases. 
Besides musculoskeletal, psychiatric and CV 
diseases, other causes of WD were relatively 
rare (Table 9). Of note, 25 (2.3%) patients 
received a WD pension due to infl ammatory 
polyarthropathies other than RA, seven of 
which were due to psoriatic and enteropathic 
arthropathies (M07), three due to juvenile 
arthritis (M08), two due to other specifi c 
arthropathies (M12), and 13 due to other 
arthritis (M13).
Aft er adjustment for competing risks, 
the 9-year cumulative incidence of WD 
resulting primarily from RA was 11.9%, 
from a psychiatric disorder 1.3%, and from 
a CV disease 0.5% (Table 10, Figure 12). 
Cumulative incidences of WD are shown 
separately for men and women in Figure 
13. WD resulting from RA was less frequent 
among women than among men (age- and 
RF-adjusted sHR 0.72, 95% CI: 0.62 to 0.83, 
p<0.001). Th e incidence of WD resulting from 
psychiatric disorders did not diff er by gender 
(sHR 1.06, 95% CI: 0.65 to 1.71, p=0.82). CV 
disease resulted rarely in WD among both 
men (16 cases) and women (14 cases). It was 
clearly less frequently the leading cause for 
WD among women than among men (sHR 
0.40, 95% CI: 0.19 to 0.81, p=0.012). 
Th e mean (standard deviation [SD]) age 
at the beginning of a disability pension was 
52.4 (7.5) years. Th e mean (SD) age diff ered 
according to the leading cause of WD: it was 
47.6 (10.2) for psychiatric disorders, 52.4 
(7.2) for RA, 55.8 (4.6) for CV disease, and 
53.4 (6.8) years for other diseases (p < 0.001).
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Figure 11. Th e cumulative percentage of hypothyroidism before RA diagnosis in men and women at 
age < and ≥70 years (unpublished results).
Results
48
Table 9. Th e number of disability pensions for diseases according to ICD-10 disease class in the 
cohort of 7,831 RA patients. 
Leading cause of disability pension Total
% of all disability 
pensions
Diseases of the musculoskeletal system (M00-M99) 873 79.7
Seropositive rheumatoid arthritis (M05) 539 49.2
Seronegative rheumatoid arthritis (M06) 200 18.3
Other infl ammatory polyarthropathies (M07-M14) 25 2.3
Arthrosis (M15-M19) 37 3.4
Systemic connective tissue disorders (M30-M36) 8 0.7
Dorsopathies (M40-M54) 42 3.8
Other diseases of the musculoskeletal system 22 2.0
Psychiatric disorders (F20-F69) 82 7.5
Schizophrenia, schizotypal and delusional disorders (F20-29) 6 0.5
Mood disorders (F30-F39) 74 6.8
Other psychiatric disorders 2 0.2
Cardiovascular diseases (I00-I99) 30 2.7
Ischemic heart diseases (I20-I25) 14 1.3
Cerebrovascular diseases (I60-I69) 11 1.0
Other cardiovascular diseases 5 0.5
Neoplasms (C00-D48) 28 2.6
Diseases of the nervous system (G00-G99) 18 1.6
Injuries (S00-T98) 14 1.3
Diseases of the respiratory system (J00-J99) 13 1.2
Diabetes mellitus (E10-E14) 8 0.7
Table 10. Numbers and cumulative incidences of work disability (WD) due to rheumatoid arthritis 
(RA), psychiatric disorders, and cardiovascular (CV) diseases in the cohort of 7,831 RA patients. A 
competing risks analysis.
    Cumulative incidence of WD
Main cause of WD n (%) % (95%CI)
       5-year follow-up    9-year follow-up
RA 739 (67.5) 10.3 (9.5, 10.9) 11.9 (11.1, 12.8)
Psychiatric disorders 82 (7.5) 1.2 (0.9, 1.4) 1.3 (1.0, 1.7)
CV diseases 30 (2.7) 0.4 (0.3, 0.6) 0.5 (0.3, 0.7)
Other 244 (22.3) 3.6 (3.1, 4.1) 5.5 ( 4.7, 6.4)
Results
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Th e incidence of WD caused by CV 
disease was higher than in the general 
population, the SIR being 1.75 (95% CI 
1.23 to 2.51). Th e incidence ratios remained 
increased among both men (1.81, 95% CI: 
1.11 to 2.95) and women (1.69, 95% CI: 
1.00 to 2.86). Th e incidence of WD due to 
psychiatric disorders was similar to that of the 
general population (SIR 0.99, 95% CI: 0.80 to 
1.23). It remained similar in both sexes, the 
SIR being 1.25 (95% CI: 0.83 to 1.88) among 
men, and 0.92 (95% CI: 0.71 to 1.18) among 
women.
Figure 14 shows the mean numbers of 
annual WD days one year before and aft er 
RA diagnosis among patients who had a 
psychiatric disorder, a CV disease or neither 
of these as evaluated by their eligibility for 
special medicine reimbursements at RA 
diagnosis. Regardless of the presence of 
comorbidities, the mean number of annual 
WD days was substantially higher one year 
aft er than one year before the diagnosis of RA. 
Although the mean number of annual work 
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Figure 13. Five- and nine-year cumulative incidences (with 95% confi dence intervals) of work 
disability (WD) due to rheumatoid arthritis, psychiatric disorders, and cardiovascular (CV) diseases 
in men and women with RA, as competing risks analysis.
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Figure 12. Competing-risks cumulative 
incidence functions for work disability 
(WD) because of rheumatoid arthritis (RA), 
psychiatric and cardiovascular (CV) diseases 
aft er RA diagnosis among 7,831 RA patients. 
Competing risks were WD caused by diseases 
other than the disease of interest and death 
before age 65. Th e gray area represents the 95% 
confi dence intervals. 
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disability days was numerically slightly higher 
in the group of patients with a psychiatric 
disorder at baseline, no statistically signifi cant 
inter-group diff erences emerged either one 
year before (age-, sex- and rheumatoid 
factor-adjusted p=0.061) or one year aft er the 
diagnosis of RA (p=0.17).
11  Cardiovascular mortality
Th e median (range) follow-up was 4 (<1–9) 
years for individual patients. A total of 1,157 
patients died during a total of 71,769 person-
years (22,471 for men and 49,298 for women). 
Th e most common underlying cause of death 
was CV disease with 501 cases, representing 
43% of deaths due to any cause (Figure 15). 
Another major group of causes of death was 
neoplasms (27%).
Of the 501 CV deaths, 314 (63%) resulted 
from ischemic heart disease (Table 11). 
Cerebrovascular disease was the underlying 
cause of death in 105 cases, comprising 21% 
of all CV deaths (Table 11). CV diseases 
other than CHD and cerebrovascular diseases 
caused less than 20% of all CV deaths. Th e 
relative proportions of diff erent CV diseases 
as causes of death were similar in men and 
women (Table 11). Only one death was caused 
by carditis, specifi cally recorded as chronic 
adhesive pericarditis (I31.0). 
 Mean annual work disability days per patient-years
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Figure 14. Unpublished results. Mean annual work disability days one year before (white squares) and 
aft er (black squares) RA diagnosis among patients who had a baseline psychiatric disorder (n=33), a 
baseline cardiovascular (CV) disease (n=796) or who had neither of these comorbidities (n=7,002). 
Th e results are presented with 95% confi dence intervals. 
Figure 15. Proportions of ICD-10 disease groups as underlying causes of death in the early rheumatoid 
arthritis cohort (n=14,878). Absolute numbers of deaths are at the ends of each column.
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Th e SMR for CV deaths in the entire 
RA cohort was 0.57 (95% CI 0.52–0.62). Th e 
SMR in subgroups according to sex and RF 
status was highest among RF-positive men 
(0.70, 95% CI 0.60 to 0.83) and lowest among 
RF-negative women (0.43, 95% CI 0.35 to 
0.53) (Figure 16). 
Th e proportion of CV deaths of all deaths 
increased towards older age groups in both 
men and women (Figure 17). At the end of 
follow-up, mean (SD) age was 77.0 (9.6) years 
for those who died of a CV cause, 72.4 (11.0) 
years for those who died of another cause, 
and 59.5 (14.5) years for those who survived. 
Women who died of CV diseases were 
generally older (mean 80 years) than the men 
who died of CV diseases (mean 74 years). 
Women and men who died of causes other 
than CV disease were more nearly the same 
age (mean ages at death 74 and 72 years). Th e 
cumulative incidence of CV death was 2.6% 
among women and 4.4% among men at fi ve 
Results
Table 11. Proportions of diff erent cardiovascular diseases as causes of cardiovascular deaths in the 
early rheumatoid arthritis cohort. 
     n (%)
ICD-10 Disease Men Women All
I05-I09 Chronic rheumatic heart diseases 1 (0.5) 1 (0.3) 2 (0.4)
I10-I15 Hypertensive diseases 1 (0.5) 7 (2.4) 8 (1.6)
I20-I25 Ischemic heart diseases 150 (70.0) 164 (57.1) 314 (62.7)
I26-I28 Pulmonary heart disease and diseases of 
pulmonary circulation
3 (1.4) 2 (0.7) 5 (1.0)
I30-I52 Other forms of heart disease 12 (5.6) 25 (8.7) 37 (7.4)
I60-I69 Cerebrovascular diseases 37 (17.3) 68 (23.7) 105 (21.0)
I70-I79 Diseases of arteries, arterioles, and capillaries 10 (4.7) 16 (5.6) 26 (5.2)
I80-I89 Diseases of veins, lymphatic vessels and lymph 
nodes, not elsewhere classifi ed
0 (0.0) 4 (1.4) 4 (0.8)
  Total 214 (100) 287 (100) 501 (100)
Figure 16. Number of cardiovascular (CV) deaths and standardized mortality ratios (SMR) by sex 
and rheumatoid factor (RF) status.
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Figure 17. Number of cardiovascular (CV) and other deaths by sex and age.
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Figure 18. Cumulative incidence 
functions for cardiovascular death with 
adjustment for competing causes of death 
aft er RA diagnosis among men (N=4,759) 
and women (N=10,119). 
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years aft er RA diagnosis, and at nine years, it 
was 5.8% and 8.4%, respectively (Figure 18). 
Based on their medicine purchases, 
82.3% of the patients were using some kind 
of RA medication (including glucocorticoids) 
for a period exceeding 90% of their individual 
patient-years (Figure 19). Only 7.3% of the 
patients used antirheumatic medications 
for less than 50% of their individual patient-
years. Glucocorticoid use was more common 
among those who died than among those 
who survived, whereas methotrexate use was 
most common among those who survived 
(Figure 20).
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Th e prevalences of cardiac disease, 
hypertension, and diabetes were higher 
among RA patients who died of CV disease 
than among those who died of other causes 
or who survived (Table 12). Asthma or 
COPD and prior malignancies, on the other 
hand, were most prevalent among those who 
died of causes other than CV disease. Use of 
CV medications was, as expected, generally 
more common among those who died of CV 
disease than among those who died of other 
causes or survived, but with statins most oft en 
used by those who survived (Table 12). 
In the multivariable competing-risks 
model (Figure 21), the highest HRs for 
CV death were linked to cardiac disease, 
Figure 19. Proportions of rheumatoid 
arthritis (RA) patients treated with any 
RA medication (antirheumatic agents or 
glucocorticoids). Th e X axis represents 
the duration of medicine use as a 
percentage of individual patient-years 
(pyrs) at risk. 
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Figure 20. Percentages of medicine-use 
duration per individual patient-
years (pyrs) in patients who died of 
cardiovascular disease (n=501), those 
who died of other causes (n=656), and 
those who survived (n=13,721). For 
diff erences between groups, age- and 
sex-adjusted p-values were calculated. 
MTX, methotrexate; SASP, sulfasalazine; 
HCQ, hydroxychloroquine; TNF, 
tumor necrosis factor inhibitors; GC, 
prednisolon.
54
Results
Table 12. Percentages of comorbidities and duration of medicine use for cardiovascular disease 
medications in patients who died of CV disease, those who died of other causes, and those who 
survived.
 
Survivors 
(n=13,721)
CV death 
(n=501)
Other death 
(n=656)
Total 
(n=14,878)
Comorbidity Prevalence in patient subsets, %
Cardiac disease* 8.2 39.5 21.3 9.8
Hypertension without cardiac disease 15.0 26.6 15.8 15.4
Diabetes 4.9 15.6 9.8 5.5
Asthma or COPD 7.7 11.2 15.4 8.2
Prior malignancy 0.9 1.2 3.8 1.0
Medication Duration of medication use of individual pyrs, %
Beta-blockers 44.6 62.0 46.2 45.6
Agents acting on the RAA system 42.6 47.6 36.0 42.4
Lipid-modifying agents 30.3 23.7 15.6 29.0
Diuretics 19.6 51.2 35.3 22.3
Calcium-channel blockers 21.0 22.4 19.6 21.0
Certain other CV drugs** 17.5 57.5 34.4 20.8
Diabetes medications, including insulin 18.9 34.9 22.7 20.1
Abbreviations: CV, cardiovascular; COPD, chronic obstructive pulmonary disease; pyrs, patient years; RAA, re-
nin-angiotensin-aldosterone
*includes CHD, chronic CHF, chronic cardiac arrythmias (with or without hypertension and hyperlipidemia)
**ATC code C01: Cardiac glycosides, class I and III antiarrhythmic agents, sympathomimetics, vasodilators used 
in cardiac diseases including organic nitrates and other cardiac preparations
hypertension, and diabetes. In addition, 
age, male sex, RF positivity, and use of 
glucocorticoids were associated with 
increased risk of CV death. A decreased 
risk of CV death was associated with female 
sex, the presence of asthma or COPD, and 
use of methotrexate. Prior malignancies 
and treatment with sulfasalazine, 
hydroxychloroquine, subcutaneous 
TNF inhibitors, or other antirheumatic 
medications did not modify risk of CV death. 
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Figures 21 A and B. Impact of patient characteristics, comorbidities, and RA medications on the 
risk of cardiovascular death in a multivariable competing-risks model. Regarding RA medications, 
sub-hazard ratios are given for impact of medicine-use duration of 10% of individual patient-years. 
*includes CHD, CHF, chronic cardiac arrhythmias (with or without hypertension and hyperlipidemia) 
Abbreviations: sHR, sub-hazard ratio; RF, rheumatoid factor; COPD, chronic obstructive pulmonary 
disease; RA, rheumatoid arthritis; MTX, methotrexate; OXI, hydroxychloroquine; SASP, sulfasalazine; 
TNF, tumor necrosis factor
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12  General discussion
Th e results of our study shed light on many 
epidemiological aspects of comorbidities 
in early RA. Th e prevalence of clinical 
comorbidities has mainly been investigated 
in established RA cohorts. Nevertheless, the 
existing literature shows that many systemic 
autoimmune and infl ammatory processes 
activate well before the clinical onset of 
RA, which may in theory lead to alterations 
in functions of many organs already in its 
preclinical phases.13 In the present study, 
we observed that RA patients, already at 
the time of diagnosis, have more clinical 
CHD and hypothyroidism than the general 
population. Moreover, their excess risk for 
hypothyroidism was more pronounced 
among younger RA patients. Th ese fi ndings 
emphasize the systemic nature of RA, and 
may also imply the presence of shared risk 
factors or pathogenetic mechanisms in 
preclinical RA phases that also elevate risk for 
CV diseases or hypothyroidism. 
Numerous epidemiological studies have 
shown that, compared to individuals without 
RA, individuals with RA are disadvantaged 
at many hard clinical end-points such as 
mortality and WD rates. In other studies, 
the excess mortality in RA has stemmed 
mainly from excess CV deaths. Th e aim of 
our mortality study was to explore whether 
CV mortality is still increased among early 
RA patients diagnosed in the 2000s, and we 
discovered no increased CV mortality. Th e 
CV disease-specifi c SMRs were, in fact, less 
than one in the entire RA population and in 
every subgroup sorted by sex and RF status. 
Th e interpretation of this result should best, 
however, be fairly conservative, because 
others’ studies have shown diff ering results, 
and because our data do not provide suffi  cient 
explanatory analyses. Nevertheless, CV 
diseases remained the leading cause of death. 
We also observed that 10% of the 
disability pensions in our RA cohort were 
caused by CV and psychiatric comorbidities, 
and that the risk for becoming work disabled 
because of a CV disease was almost twice as 
high as in the general population. All these 
fi ndings together stress the importance of 
comprehensive clinical examinations and 
alertness for comorbid conditions in patients 
diagnosed with RA, already in the early years 
of the disease. 
As multimorbidity has vast eff ects on 
disability, mortality, quality of life, and even 
the treatment of RA itself, it should become 
an important target in the medical care of 
RA patients. Keys to optimize the prevention 
of comorbidities in RA include annual and, 
ideally, structured screening for comorbidities, 
and a multidisciplinary approach to 
comorbidity care, involving rheumatologists, 
other specialists, primary-care practitioners, 
and allied health professionals.283 Because 
systemic infl ammation seems an important 
DISCUSSION
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mechanism in the development of multiple 
comorbidities in RA, tight control of 
disease activity is central in order to prevent 
comorbidity. Paying attention to common 
risk factors for many diseases such as 
smoking, physical inactivity, and unnecessary 
use of glucocorticoids is also helpful. Based 
on the higher relative risk for comorbidity, 
attention should focus upon the prevention 
of comorbidities in young and early-onset 
RA patients, whereas among older patients, 
comorbidities should be targeted based on 
their higher absolute risk. 
Identifi cation of RA patients relied on 
the combination of a rheumatologist’s clinical 
diagnosis, commencement of antirheumatic 
medication, and the allowance of special 
reimbursement for those medications. Th is 
is a sensitive case identifi cation method, as 
indicated by the RA incidence of 44.5/100,000 
patient-years over the years 2000 to 2007, 
which is slightly higher than in earlier Finnish 
studies using the ACR criteria31,32 and similar 
to or slightly higher than incidence rates 
reported recently in north Europe or North 
America.284-286 A major strength of these 
studies was that we were able to compare the 
RA cohorts with the age- and sex-specifi c 
general population regarding all important 
outcomes, and thus gain reliable information 
on their relative risks. 
13  Comorbidities at diagnosis 
of RA
We observed that, based on the eligibilities for 
special medicine reimbursements, 20% of the 
14,878 RA patients already had hypertension, 
9% had asthma or COPD, 8% had CHD, 6% 
had diabetes, and 5% had hypothyroidism 
before RA diagnosis. In another Finnish 
cohort of 87 patients with early RA collected 
between 1986-1989 from the Helsinki area, the 
prevalences of comorbidities, as recognized 
by interview and confi rmed from patients’ 
medical records, were lower at RA diagnosis 
than in our study: 9% of those patients had 
hypertension, 2% had asthma or COPD, 1% 
had COPD, and 1% had diabetes.69 A recent 
Dutch study among a cohort of 3,354 patients 
with newly diagnosed infl ammatory arthritis 
from 2001-2010 using data from electronic 
patient records in general practice discovered 
that the prevalence of a chronic comorbidity 
at the onset of the disease was as high as 
70%.287 Th is was signifi cantly higher than in 
the controls without infl ammatory arthritis 
matched at a 2:1 ratio by age, sex, and general 
practice, among whom the prevalence of any 
comorbidity was 59%.287 Th e most common 
comorbidities for infl ammatory arthritis were 
CV diseases (35%), musculoskeletal diseases 
(27%), and neurological diseases (22%).287 
Prevalence estimates for comorbidities in 
that study may be higher than ours because 
of diff erences in their case identifi cation 
methods – our case identifi cation was based 
on special medicine reimbursements, which 
may result in a suboptimal coverage of some 
comorbidities because not all chronic diseases 
or milder disease forms qualify for special 
medicine reimbursements in Finland, and 
some diseases do not even require continuous 
medication. 
13.1  Coronary heart disease
We observed a slightly but signifi cantly 
increased risk for CHD among patients 
with newly diagnosed RA already at the 
time they were prescribed antirheumatic 
medication (Table 7). Although the literature 
has implied that increased risk for CHD 
exists in the early years of RA,13,169,176 what 
remains to be ascertained is how early this 
risk increases.175,176 An American population-
based cohort study in the framework of the 
Rochester Epidemiology Project showed 
that patients with RA were at increased risk 
for CHD already during the two-year period 
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before the fulfi llment of the ACR 1987 criteria 
for RA.169 During that period, the RA patients 
were much more frequently hospitalized for 
acute MI (OR 3.17, 95% CI 1.16-8.68) and 
experienced more unrecognized MIs (OR 
5.86, 95% CI 1.29-26.64) than did non-RA 
controls.169 On the other hand, a Swedish 
study on 7,469 RA patients disclosed an 
increased risk for myocardial infarction only 
one year aft er fulfi llment of ACR criteria for 
RA, but no increased risk before the onset 
of RA symptoms.72,175 Together with the 
study from Rochester, Minnesota, our study 
supports an increased risk of CHD already 
preceding the full clinical eruption of RA. 
As CV risk seems to increase already 
before the clinical symptoms of RA, what 
mechanisms do underlie this fi nding? 
As shown by the presence of RA-related 
autoantibodies as well as elevated cytokine 
and chemokine levels, systemic infl ammation 
and autoimmunity in RA begin years before 
the onset of detectable joint infl ammation.24,124 
In theory, these preclinical autoimmune and 
infl ammatory processes may increase CV risk 
before the clinical onset of RA. In addition, 
our fi nding brings forth the role of shared 
risk factors underlying the co-existence 
of RA and CV disease. One of these risk 
factors is undoubtedly smoking.74,114 With 
regard to genetic factors, a British study on 
more than 1,000 patients with infl ammatory 
polyarthritis showed that carrying two copies 
of SE alleles, a risk factor for the development 
of ACPAs,16 predicted death from CV disease 
(HR 1.68, 95% CI 1.1-2.7).63 Th e combination 
of SE, smoking, and anti-CCP antibodies 
elevated risk even further (HR 7.81, 95% 
CI 2.6-23.2). Many other RA-related 
polymorphisms in genes such as TGFβ1, 
factor XIIIA, IRF5, PAI-1, TNF-α, TNFR II, 
NFKB1, and MTHFR apparently modulate 
risk for CV disease in RA.74,288-292
When we examined the eff ect of age 
at RA onset on CHD risk, we made two 
observations. Firstly, CHD prevalence 
increased towards older age groups, as it 
does in the general population (Figure 7). 
Secondly, the rate ratio of having CHD 
prior to RA diagnosis seemed higher among 
younger than among older age groups (Figure 
6), but power to prove this trend statistically 
signifi cant was lacking. Similar fi ndings 
emerge in established RA populations: 
for example, Naz and coworkers studied a 
cohort of 1,098 patients with infl ammatory 
polyarthritis from 1990-94 and observed 
the highest CV death rates to be among the 
RF-positive patients who were younger than 
55 at RA-symptom onset.138 A large Swedish 
study on almost 50,000 RA patients from 
1964-95 reported a fi ve-fold risk for coronary 
death among female patients who were age 
20-39 at fi rst RA-related hospital discharge, 
whereas the risk of coronary death rose 
by only 80% in the entire RA cohort.64 In 
addition, in an American cohort of 25,385 
RA patients in 1999-2003, the rate ratio of 
hospital admissions for CV disease was 3.3 
among patients aged 18 to 39 years vs. 1.6 
among those ≥75 years, whereas the absolute 
rate diff erence between RA patients and 
non-RA controls was 1.2 vs. 19.7 per 1,000 
person-years in the respective age groups.165
Th ese studies suggest that earlier-onset 
RA may confer a higher relative risk for 
CHD than does later-onset RA.64,138 Th is 
premise is reasonable, since if sustained 
remission is not achieved with antirheumatic 
therapy, the earlier a patient contracts RA, 
the longer systemic infl ammation damages 
the vasculature. Although we investigated 
CHD prevalence at the time of RA diagnosis, 
we nevertheless observed the highest SRR 
point estimates among the youngest patients. 
One explanation for our suggestive fi nding 
is at least in part the concept of competing 
risks: since age is such an important risk 
factor for CHD, it leads to a reduction in 
the relative contribution of other CHD risk 
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factors, including RA.165 Absolute excess risk, 
however, might be even higher in patients 
with late-onset RA than in those with early-
onset RA, as indicated by our observation of 
a very low prevalence of CHD among patients 
aged less than 60 (Figure 7). 
Although both the RF-positive and 
RF-negative patients had higher prevalences 
of CHD than expected based on the rates in 
the general population, only the RF-negative 
patients reached statistical signifi cance. Most 
studies have found RF to associate with 
higher risk for CV events. Our fi nding is not 
necessarily contradictory to theirs, because 
we looked at the CV risk before RA; earlier 
studies focused mainly on established RA.60 
Since RF-positive RA is linked to higher 
disease activity and a poorer prognosis than is 
RF-negative RA,293 the ongoing higher level of 
infl ammation may result in a higher risk for 
CV events as disease duration lengthens. Nor 
did one Swedish study examining myocardial 
infarction risk at RA onset fi nd RF positivity 
linked to CV risk.175 
As in the general population, men with 
RA had a considerably higher prevalence 
of CHD (11.5%) than did women with 
RA (5.9%). Rate ratios of CHD, however, 
remained fairly similar by gender (Figure 
6). Th ese fi ndings are in line with previous 
fi ndings of higher absolute but similar relative 
risk for CV disease among male compared to 
female RA patients.165,175,177,294 For example, 
in a population-based study on 25,000 RA 
patients from British Columbia, Canada, 
the rates of a combined CV outcome of 
myocardial infarction, stroke, and CV death 
were 12.4 per 1,000 person-years among 
women and 20.1 among men, whereas the 
rate ratio was 1.6 among both sexes.165
In short, relative risk for CHD was 
already higher in RA patients at the time of 
diagnosis. Based on the literature review, both 
asymptomatic atherosclerosis and overt CV 
events occur at a higher than expected rate 
shortly aft er the fi rst RA symptoms emerge. 
Speculatively, because reversal in CV changes 
may occur aft er successful antirheumatic 
treatment, a window of opportunity may 
exist not only for treatment of RA but also for 
RA-exacerbated CV disease.168,295 Our fi ndings 
highlight the importance of early prevention 
of atherosclerosis in RA, regardless of RF 
status. 
13.2  Chronic hypertension
Based on special-reimbursement-decision 
data, hypertension was the most common 
comorbidity at RA diagnosis in Finland in 
2000-2007 with a prevalence of 20%. Similarly, 
in another Finnish study on a cohort of 87 
patients with early RA, hypertension was the 
most common comorbidity, its prevalence 
being 9% at RA diagnosis and 30% aft er 15 
years of follow-up.69 Our fi ndings are also 
comparable to those of a Swedish prospective 
cohort study, in which the prevalence of 
antihypertensive treatment at RA diagnosis 
was 24.6%.85
Th e existing literature is inconsistent 
on whether hypertension, an important 
traditional CV risk factor, is less prevalent 
with no RA than in RA patients.104,105,296,297 
One meta-analysis pooling the results of 15 
case-control studies disclosed a prevalence 
of hypertension similar among RA patients 
and controls.84 In line with this, we found 
no increased risk for hypertension at RA 
diagnosis when looking at the entire RA 
cohort. When looking at the subgroups of 
RF-positive and -negative patients, however, 
we observed a slightly increased prevalence 
of chronic hypertension only among the 
RF-negative subgroup. Although we present 
no explanatory fi ndings for this observation, 
it is consistent with our observations 
regarding risk for CHD. Interestingly, a recent 
study from the Rochester Epidemiology 
Project suggested that RA patients have more 
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long-term variability in blood pressure than 
do non-RA controls, and that this may be 
associated with adverse CV outcomes.298
13.3  Congestive heart failure
Various studies have reported that RA patients 
carry an excess risk for CHF.104,178,299,300 A 
population-based, retrospective incidence 
cohort study in Rochester, Minnesota, 
indicated that the increased risk for CHF 
among RA patients exists in all age groups 
and may already be present at the index 
date.178 Regarding the RA population as a 
whole, they detected a 1.7-fold incidence of 
CHF. In addition, the higher risk for CHF was 
more pronounced among women and among 
those RF-positive.178
We observed a similar risk for CHF in 
our RA inception cohort and in the general 
population. Since CHF frequently results 
from injury to the myocardium resulting from 
ischemic heart disease or hypertension,301 
it seems logical that it is not highly frequent 
among RA patients until such diseases have 
been established for awhile. In addition, these 
fi ndings are in line with the observation that 
diastolic dysfunction may be linked to RA 
duration.153-155
13.4  Diabetes and dyslipidemia
Many studies examining associations 
between RA and diabetes mellitus have 
reported them to co-exist at a rate higher than 
expected.4,84,104,302,303 In a large population-
based study of over 28,000 RA patients 
compared with more than 100,000 controls, 
the prevalence ratio for diabetes was 1.4.104 
According to a study on 48,718 RA subjects, 
a relative risk for diabetes mellitus, mostly 
type II, was elevated in both genders but risk 
decreased with age.303 One meta-analysis 
assessing the prevalence of CV risk factors 
in RA concluded that the OR (95% CI) for 
diabetes was 1.74 (1.22 to 2.50).84 Some studies 
have, however, observed no association 
between the two conditions.105,106,297 With 
regard to early RA, severe insulin resistance 
characterized 66 untreated RA patients with 
disease duration less than one year.102 
We observed no diff erence in risk 
for diabetes between newly diagnosed 
RA patients and the general population. 
Th is fi nding suggests that if the systemic 
infl ammation of RA indeed accelerates the 
development of insulin resistance,100,101,304 it 
may not manifest as type II diabetes mellitus 
very early in  the course of RA. Th is hypothesis 
needs testing in even larger studies with better 
sensitivity to type II diabetes mellitus and its 
early manifestations. Of note, we detected no 
elevated prevalence of special reimbursement 
for medications for dyslipidemia, although 
the prevalence of CHD was slightly higher 
than in the general population. 
13.5  Assessment and 
management of CV risk in 
RA
CV risk assessment in RA is an important 
clinical issue lacking unambiguous evidence-
based treatment guidelines. Th e EULAR 
recommendations for CV risk management 
in patients with RA and other forms of 
infl ammatory arthritis suggest that, along 
with early and eff ective antirheumatic 
treatment, an annual CV risk assessment 
and intervention is necessary, following local 
treatment guidelines.231 Furthermore, to take 
the additional RA-related CV burden into 
account when using CV risk-score calculators, 
these recommendations suggest adding a 
multiplication factor of 1.5 if the RA patient 
meets two of the following three criteria: 1) 
disease duration of more than 10 years, 2) 
RF or ACPA positivity, and 3) the presence 
of certain extra-articular manifestations.231 
Based on our conducted review13 and 
results (Study I), however, atherogenesis 
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and development of CV diseases may in fact 
accelerate already in the earliest phases of RA. 
Moreover, the increased CV risk seems not to 
be confi ned only to those seropositive, but to 
be elevated also among seronegative patients, 
as indicated by both our own fi ndings and 
earlier studies.72,175,190,305 Th erefore, even aft er 
applying a multiplication factor to CV risk-
score calculations by these three criteria, CV 
risk may still be underestimated, especially 
for patients with early RA and seronegative 
disease. 
Th e use of beta-blockers, of agents acting 
on the renin-angiotensin-aldosterone system, 
and of lipid-modifying agents was relatively 
common in our RA cohort – the duration of 
their use covered 46%, 42%, and 29% of all 
patient-years in the cohort (Study IV, Table 
12). As these medications have been shown 
to improve the prognosis of patients with 
CV disease,306 it is vitally important that RA 
patients at risk receive them. Beta-blockers 
and agents acting on the renin-angiotensin-
aldosterone system were, however, only 
moderately more oft en prescribed and, 
alarmingly, statin use was lower among those 
who died of CV disease than among those 
who survived (Table 12), perhaps refl ecting 
inadequate secondary prevention of CV 
events among those patients. Th is speculation 
is supported by a nationwide Danish study on 
more than 66,000 patients with fi rst-time MI, 
in which an RA diagnosis was associated with 
reduced initiation of aspirin, beta-blockers, 
and statins as secondary prevention.237 
Moreover, in the same study, adherence to 
statin therapy was poorer among RA patients 
than among non-RA patients.237
13.6  Hypothyroidism
Th e present study demonstrated a positive 
association between RA and hypothyroidism 
already at RA diagnosis. Chronic 
autoimmune thyroiditis, the most common 
cause of hypothyroidism, has been highly 
prevalent among established RA patients in 
numerous investigations. A systematic review 
on this topic showed, however, that most of 
these fi ndings are derived from uncontrolled 
case series or small case-control studies 
from tertiary care settings.5 Th ese authors 
found eight studies between 1963 and 2001 
examining the prevalence of comorbid 
autoimmune thyroiditis among an RA index 
population; the prevalence of thyroiditis 
ranged from 0.5% to 9.8%.252-254,307-311 Only 
four of these were controlled studies,253,254,307,311 
and only two of them showed a signifi cantly 
higher prevalence of autoimmune thyroiditis 
among the RA patients than among controls.5 
When considering RA prevalence in an index 
population with autoimmune thyroiditis, 
the review authors observed no consistent 
association.5 Another meta-analysis showed 
that thyroid autoantibodies were more 
prevalent in RA than in healthy controls 
(OR 3.17, 95  % CI 2.24 to 4.49 for TgAb; 
OR 2.33, 95 % CI 1.24 to 4.39 for TPOAb).312 
Few studies have, in fact, looked into the 
prevalence of hypothyroidism in an RA index 
population at RA onset.
A pair of large high-quality studies off er 
results similar to ours. Th e most important 
is undoubtedly the population-based cohort 
study from the United Kingdom, which 
included, from 1990 to 1999, 22,888 patients 
with RA and 26,198 with autoimmune 
thyroiditis. It found a moderate bidirectional 
association between RA and autoimmune 
thyroiditis, the SIR for thyroiditis being 1.62 
among the RA index population, and the 
SIR for RA being 1.32 among the thyroiditis 
index population.4 In a recent Swedish study 
among 1,998 patients with incident RA from 
1996 to 2006, individuals with levothyroxine 
substitution (6%) were at twofold risk for 
developing both ACPA-positive and ACPA-
negative RA.251 
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Assuming that most of the Finnish RA 
patients using levothyroxine substitution 
have hypothyroidism resulting from chronic 
autoimmune thyroiditis,313 our results lend 
further support to the hypothesis that the 
high co-existence of these diseases results 
either from common risk factors or shared 
pathogenetic mechanisms. For example, 
the PTPN22 risk allele may be a common 
susceptibility allele to RA and to autoimmune 
thyroiditis.250,258 In addition, evidence from 
similar cytokine profi les in these diseases 
suggests that both are Th 1-associated,5 
although Th 17-cells may also play a part 
in RA pathogenesis.314 In one study, the 
prevalence of antinuclear autoantibodies in 
autoimmune thyroiditis was as high as 45%,257 
perhaps implying a higher vulnerability to 
autoimmune rheumatic diseases among these 
patients.
Our results demonstrate that the relative 
risk for hypothyroidism among younger 
compared to older patients with newly 
diagnosed RA is higher (Figure 9). In line 
with this fi nding, particularly the young 
patients with an autoimmune disease may be 
at increased risk for comorbid autoimmune 
thyroiditis.315 Th e risk for hypothyroidism 
was 2.5-fold among women younger than 
50 at RA diagnosis. Our fi ndings should 
encourage clinicians to check thyroid 
hormone levels of RA patients with any 
symptoms of hypothyroidism, and to be alert 
to the possibility of RA as the underlying 
cause of joint symptoms in young patients 
with hypothyroidism. 
Although the rate ratio of hypothyroidism 
was higher among younger than among 
older age groups, its absolute prevalence 
followed the opposite trend (Figure 10). As 
with CHD, high age being a risk factor for 
hypothyroidism, the relative impact of RA on 
overall risk for hypothyroidism may decrease 
as one ages. Th e absolute excess risk for 
hypothyroidism, on the other hand, increases 
with age. Vigilance for hypothyroidism is 
therefore equally justifi ed among old and 
young RA patients. 
Th e prevalence of hypothyroidism 
among our female RA patients was 6.6%. 
A recent Dutch population-based study 
reported that in a cohort of 175,000 primary-
care patients, hypothyroidism prevalence 
among female patients with infl ammatory 
arthritis was surprisingly similar, 6.5%,316 
corresponding to a 2-fold higher risk than 
that of controls. Risk for hypothyroidism is 
well acknowledged to be many times higher 
among women than men and, consistent 
with that, the prevalence of hypothyroidism 
was 5.5-fold among our female compared to 
our male RA patients. SRR point estimates 
were, however, similar by gender (1.39 for 
men and 1.52 for women), but the lower 
95% confi dence limit was higher than 1.0 
only among women, most likely because of 
a lack of power among men. Th us, studies 
conducted in even larger RA populations 
are warranted to confi rm our fi nding among 
men.
We demonstrated similar prevalences 
and SRRs of hypothyroidism among RA 
patients RF-positive and RF-negative. 
Th e impact of RF status on risk for 
hypothyroidism has been only rarely noted. 
In those relatively small study populations, 
RF has been either less or equally prevalent 
among RA patients with thyroid dysfunction 
than among euthyroid RA patients.254,317
In theory, the symptoms of insidious-
onset RA such as fatigue and arthralgia could 
mimic those of hypothyroidism and lead 
to more frequent testing and diagnosing of 
thyroid disorders in some patients diagnosed 
with RA a few months later. Th is potential 
source of bias might have elevated SRRs for 
hypothyroidism in our RA cohort. To validate 
our results in this respect, we evaluated 
SRRs for hypothyroidism one year before 
RA diagnosis. Compared to values at RA 
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diagnosis, the SRRs remained unchanged, 
thus lending support to our results. 
Th yroid defi ciency may play a role 
in the development of CV disease both in 
the general population318 and in RA.6,316,319 
One Dutch study including 236 women 
with RA disclosed that, in addition to a 
threefold risk for hypothyroidism among 
female RA patients compared to that of the 
general population, the presence of clinical 
hypothyroidism was associated with a 
fourfold risk for CV disease compared with 
that of euthyroid women with RA (HR 4.1, 
95% CI 1.2 to 14.3).6 In an American study 
using data from the Rochester Epidemiology 
Project, hypothyroidism was not more 
prevalent among the 650 RA patients than 
among 650 controls, but it was associated with 
CVD in patients with RA (HR 2.1, 95% CI 
1.1 to 3.6).319 In the light of these studies, we 
wanted to investigate whether any clustering 
occurred between CHD and hypothyroidism 
in individuals with future RA. In this Finnish 
RA cohort, however, CHD prevalence was 
similar among patients with and without 
levothyroxine substitution at RA diagnosis.
14  Comorbidities as causes of 
work disability
To date, the literature on the role of 
comorbidities in leading to WD in RA 
has been surprisingly limited. Our study 
addressed, to our knowledge for the fi rst 
time, the question of how oft en psychiatric 
and CV comorbidities in RA lead to long-
term WD. We found that CV and psychiatric 
comorbidities were the leading cause of 
a disability pension in only 10% of all 
permanently work-disabled RA patients; 
and they therefore seem to play a relatively 
modest role as the leading causes of long-
term WD in RA. Noteworthy is that RA and 
other diseases of the musculoskeletal system 
comprised the leading causes of 80% of all 
WD cases. Our fi ndings are comparable with 
those of a British study of an inception cohort 
of 1,460 RA patients diagnosed in 1986-1998 
and followed up for a median of 10 years.320 In 
that study, comorbidity was the main reason 
for stopping working for only 8.7%, and RA 
together with a comorbidity led to 13.8% 
of the work cessations. Th e comorbidities 
were most oft en CV diseases, chronic 
lung diseases, and psychiatric disorders. 
Approximately 50% of the work cessations 
were related to RA without the contributory 
eff ect of comorbidity, and the rest were due to 
reasons not related to health such as planned 
age-related retirement and personal or social 
reasons.320 
In established RA, depressive symptoms 
are highly prevalent,321 and depression may 
be more common in RA than in the general 
population. In a Finnish study of an RA 
cohort similar to ours, that is, all ≥50-year-old 
RA patients diagnosed in Finland in 2000-
2007, 10.0% used antidepressants during 
the year antedating their RA diagnosis, and 
by the end of 2008, 9.4% more had initiated 
antidepressant medication.322
Although an association between WD 
and depressive symptoms or anxiety as 
evaluated by self-assessment questionnaires 
has been apparent in some small RA 
populations,10-12 no studies to date have 
assessed the role of clinical psychiatric 
disorders as the leading causes of long-term 
WD in RA. Our results show that psychiatric 
disorders were, aft er musculoskeletal diseases, 
the second most frequent group of chronic 
diseases leading to long-term WD in recent-
onset RA. Nevertheless, they accounted for 
only some 8% of all disability pensions (Table 
9). 
Compared to the general population, the 
risk for permanent WD caused primarily by 
a psychiatric disorder was not increased. Th is 
fi nding is in line with the Finnish study, in 
which the prevalence of antidepressant use 
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among RA patients was not higher than in 
the general population.322 Our results indicate 
that even though depression and other 
psychiatric disorders are likely to contribute 
to the development of WD in RA, their eff ect 
on work ability rarely exceeds that of RA 
itself. 
In our RA cohort, CV disease was the 
leading cause of WD almost twice as oft en 
as it is in the general population. Th is can 
be rather eff ortlessly explained by the widely 
documented increased CV morbidity in RA. 
As RA patients are reported to be at CV risk 
similar to that of individuals without RA 
who are 5 to 10 years older,168 it is reasonable 
to expect disparities in rates of WD caused 
by CV disease. Th is fi nding provides 
rheumatologists and other healthcare 
professionals an additional reason to target 
CV comorbidities in RA aggressively.
When considering the absolute 
incidences of WD instead of incidence 
ratios, CV disease accounted for less than 
3% of all disability pensions, indicating that 
its signifi cance as a leading cause of WD in 
RA is limited. Comorbidities may, however, 
compromise the work capacity of RA 
patients without leading to long-term WD, 
and it may be diffi  cult to determine which 
disease reduces work capacity the most in 
multimorbid patients. Hence, although only 
a small portion of the disability pensions in 
our RA cohort resulted primarily from CV 
or psychiatric comorbidities, these diseases 
may be more signifi cant when considering 
their contributory impact on WD that results 
primarily from RA or other musculoskeletal 
conditions. Th is theory, however, was not 
supported by our observation of similar 
numbers of WD days one year before and 
aft er RA diagnosis in patient subsets with 
or without baseline CV or psychiatric 
comorbidities.
Male sex being a risk factor for CV 
disease, men with RA had higher rates of 
WD caused by CV disease than did women. 
Men may also be occupied in more physically 
demanding jobs,320 making their ability to 
work aff ected to a greater extent by physical 
limitations imposed of their CV disease. 
Despite this, the percentage increase in 
incidence of WD resulting from CV disease 
compared to that of the general population 
was similar by gender. Th ese fi ndings are 
in line with those of higher incidences but 
similar incidence rate ratios of CV events 
among men than among women with 
RA.323,324 As to WD resulting from psychiatric 
disorders, both the absolute incidences and 
incidence ratios of WD were similar between 
genders. 
RA patients who were granted a 
disability pension for a psychiatric disorder 
were considerably younger than those who 
became work disabled because of RA or a 
CV disease – mean age at the beginning 
of a disability pension was 48 vs. 52 and 56 
years, respectively. When refl ected against 
a common statutory retirement age of 65 
years in Finland, these ages equal a mean 
number of 17 vs. 9 or 13 lost years at work. 
Psychiatric disorders are therefore likely to 
lead to relatively higher productivity losses 
and societal costs than expected based on 
mere WD incidences. For a rough estimate 
of lost productivity, the average monetary 
value of annual productivity of an employed 
Finnish resident was 73,623 euros in 2000–
2008 (amount expressed at the 2012 level).278
Of note, musculoskeletal diseases other 
than RA were the leading WD cause in 12% 
of this RA population, mainly represented by 
degenerative disorders such as back pain and 
osteoarthritis (Table 9). Th is highlights the 
fact that in the era of modern RA treatment 
regimens and decreasing WD rates for RA,49 
not uncommonly does the disability of an RA 
patient result actually from a musculoskeletal 
disease other than RA, these diseases 
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commonly leading to WD also in the general 
population. 
Interestingly, the diagnostic ICD-10 code 
in the pension register was for 25 patients 
an infl ammatory polyarthropathy other 
than RA. Th is is 3.4% of the patients whose 
WD pension diagnosis was RA. Th is fi nding 
refl ects the real-life diagnostic challenges 
in infl ammatory rheumatic diseases. Some 
patients may display features of more than 
one infl ammatory arthritis, such as RA 
and psoriatic arthritis, so that selecting 
the diagnosis for these patients is not 
straightforward. Mistakes may also appear in 
medical certifi cates. Overall, the number of 
patients whose diagnosis changed from RA 
to another infl ammatory polyarthropathy was 
small, suggesting that identifying RA patients 
based on special reimbursement decisions is 
adequately accurate. 
In the aggregate, psychiatric and CV 
comorbidities were the leading causes of 
disability pensions much less frequently 
than was RA itself. Risk for WD due to CV 
diseases was higher in early RA than in the 
general population, whereas WD risk due 
to psychiatric disorders was not increased. 
Optimized care of both CV and psychiatric 
comorbidities in RA may aid, among other 
eff orts, in preventing WD.
15  Cardiovascular mortality
Our fi ndings demonstrate that Finnish 
patients with early RA are at no increased risk 
for CV mortality, at least during a follow-up 
of less than 10 years. In fact, the CV disease-
specifi c SMR and its confi dence intervals were, 
surprisingly, less than one in the entire RA 
population and in every subgroup according 
to sex and RF status, implying a reduced CV 
mortality in this early RA cohort compared to 
that in the Finnish population. Interpretation 
of this result, however, requires caution 
because we had no suffi  ciently explanatory 
fi ndings, and because most studies display 
confl icting results. For example, a meta-
analysis of 17 studies conducted mainly 
among established RA cohorts revealed a CV 
disease-specifi c meta-SMR of 1.6, with SMRs 
of individual studies ranging from 0.91 to 
2.20.57 Another meta-analysis comprising 24 
studies demonstrated a CV disease-specifi c 
meta-SMR of 1.5.1 Noteworthy is the fact that 
the latter meta-analysis detected no increased 
risk of CV death among the four inception 
cohort studies, the CV-disease-specifi c meta-
SMR’s being 1.19 (95% CI 0.86–1.68).1 Th e 
comparability of our results to these meta-
analyses is, however, limited, because almost 
all of these cohorts were studied before the 
2000s and comprised patients with established 
RA, whereas our cohort was an inception 
cohort from the 2000s. Of note, neither was 
the overall survival in our RA cohort inferior 
to that of the general population.60 
Our short follow up-period is 
another important factor that may partly 
explain the low SMRs we observed. Many 
epidemiological studies have indicated that 
increased CV mortality emerges only 7 to 10 
years aft er RA diagnosis.59,175,183,189 A British 
multicenter inception cohort study has 
implied that, among RF-positive patients, 
increased CV mortality may already arise fi ve 
years aft er RA diagnosis.138 In our RA cohort, 
as well, CV mortality may exceed that of the 
general population aft er a longer follow-up. 
Moreover, it would be most interesting to 
see corresponding results with a fi ve-year 
follow-up extracted from similar research 
settings abroad.
Speculatively, a shift  towards more 
aggressive DMARD therapy during the 
past 20 years may have contributed to our 
RA cohort’s favorable CV prognosis. In one 
British register study among successive RA 
cohorts, all-cause and CV-disease specifi c 
mortality rates decreased from 1990 to 
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2011, although the reduction was similar to 
that of the general population.68 A decline 
in deaths from acute myocardial infarction 
was shown in an earlier American study in 
three successive RA cohorts followed up 
for almost 20 years: in the cohort with RA 
incidence before 1970, the SMR (95% CI) was 
1.60 (1.20 to 2.14); in the cohort from 1970 
to 1979, it was 1.83 (1.45 to 2.30); and in the 
cohort from aft er 1980, it was 1.3 (0.94 to 
1.75), suggesting that the most recent cohort’s 
risk was not statistically diff erent from that 
of the general population.66 Rantalaiho and 
coworkers have demonstrated that, in the 
same RA population that we studied, the 
initial treatment strategy of RA has become 
more modern between 2000 and 2007: during 
the fi rst three months of RA, the proportion 
of RA patients using a combination therapy 
of two or more DMARDs increased from 
38% to 55%, and the proportion receiving 
any DMARD was as high as 93 to 95%.325 
Hydroxychloroquine use increased from 50% 
to 60%, and methotrexate use from 44% to 
69%.325 
Th eoretically, the fact that RA patients 
usually visit a doctor on a regular basis 
may have led to intensifi ed diagnostics and 
prevention of CV disease. Furthermore, a 
rheumatologist may consult a cardiologist 
within a special healthcare setting more easily 
than would a general practitioner who carries 
out CV risk management in primary health 
care. Most data from other countries suggest, 
however, that RA patients are less likely to 
be prescribed CV medicines than are non 
RA-patients, not the converse.236,237 
Factors associated with an increased 
risk of CV death included male sex, RF 
positivity, diabetes, hypertension, and cardiac 
disease. Th e impacts of these comorbidities 
on CV mortality were stronger than those 
of RA medications: the sHRs for diabetes, 
hypertension, and cardiac disease were 
between 2.02 and 2.90, whereas the sHRs for 
RA medications were between 0.95 and 1.26 
(Figures 21 A and B). Th e fi ndings of male 
sex and RF as increasing the absolute risk of 
CV death were unsurprising and consistent 
with previous reports on both RA128,138 and 
non-RA cohorts.326 RF positivity and male sex 
appeared also to associate with higher SMR 
point estimates, although the only statistically 
signifi cant subgroup diff erence was between 
RF-positive men and RF-negative women 
(Figure 16). Th is extends earlier observations 
of RF’s associating with higher SMRs for CV 
death,137 but diff ers from ones suggesting that 
SMRs for CV death among men are similar1 
or lower67,190 than among women with RA.
Another factor associated with 
increased risk of CV death was use of 
glucocorticoids. Th is is in line with many 
epidemiological fi ndings of an association 
between glucocorticoids and CV events and 
death.216,217,327 Th is association, however, is 
at least partly explained by confounding 
by indication, that is, confounding by high 
disease activity being both an indication 
for glucocorticoids and a risk factor for 
CV disease.222 Correcting such bias with 
statistical adjustments in observational 
studies is challenging, and suffi  ciently 
powered randomized controlled trials are 
thus warranted to discover the true benefi t-
risk ratio of glucocorticoids in relation to CV 
disease.328
Along with sulfasalazine, methotrexate 
was the most commonly used antirheumatic 
drug: of all patient-years in the follow-up, 
its use covered almost 40%. In contrast to 
glucocorticoids, methotrexate was associated 
with a slightly decreased risk of CV death 
(Figure 21 B). Th is fi nding is parallel with 
many epidemiological observations of an 
inverse association between methotrexate 
and CV morbidity or mortality.197-200 
Infl ammation’s being a major driver of 
atherothrombosis, the protective eff ect of 
methotrexate is likely from a reduction in 
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systemic infl ammation via its eff ects on 
the IL-6 signaling pathway.329 It may also 
have direct cardioprotective eff ects through 
facilitation of reverse cholesterol transport 
and subsequent prevention of macrophages 
diff erentiating to lipid-loaded foam cells.330 
A recent study in a murine model of 
infl ammatory vasculopathy indicated that 
methotrexate may protect endothelium 
by upregulating cytoprotective genes via 
activation of AMP-activated protein kinase 
and cyclic AMP response element-binding 
protein.40
As in the case of glucocorticoids, we 
cannot exclude the possibility of confounding 
by indication or contraindication as distorting 
the relation between methotrexate and CV 
mortality: those who stop using methotrexate 
due to adverse eff ects or ineffi  cacy may 
develop more comorbidities or may suff er 
from uncontrolled infl ammation while 
searching for optimal RA pharmacotherapy, 
thus being at higher CV risk. In one German 
one-center mortality study, discontinuation 
of methotrexate during the fi rst year of its 
use led to 5.6-fold mortality compared to 
that of an age- and sex-matched sample of 
the general population.331 Furthermore, not 
all studies have found an association between 
methotrexate and risk for CV events.201,202 
Importantly, randomized controlled trials on 
this topic are on their way.205 Before receiving 
such studies’ results, no defi nitive conclusions 
on the eff ect of methotrexate on CV events 
are possible. 
Accumulating evidence shows that TNF 
inhibitors reduce the risk for CV events.201,206 
Our fi ndings regarding subcutaneous TNF 
inhibitors, however, failed to demonstrate 
such a protective eff ect. Th is is likely to result 
from TNF inhibitors’ being so infrequent in 
Finland during the follow-up period (Figure 
20). Moreover, we were unable to obtain 
data on intravenous TNF inhibitors, which 
comprised a substantial proportion of the 
TNF inhibitors especially in the fi rst years 
of our follow-up. According to data received 
from the Finnish national register for biologic 
treatment in rheumatic diseases (ROB-
FIN), a prospective cohort study covering 
the majority of Finnish patients on biologic 
agents, only 4.1 to 6.9% of RA patients 
treated with biologic agents in 2000-2002 
received them subcutaneously.332 In 2003, the 
respective percentage increased to 44.7%, and 
in 2004-2008, it further increased to 71.6 to 
80.2%.332 For these reasons, our analysis may 
misjudge the eff ect of TNF inhibitors on CV 
mortality.
Hydroxychloroquine was prescribed 
frequently for patients in our cohort 
(Figure 20). Although it has theoretical 
cardioprotective properties through benefi cial 
eff ects on lipid metabolism, platelet function, 
and diabetes control,209,210,212,333 in our analysis 
it did not aff ect CV survival. 
In sum, our fi ndings suggest that in the 
2000s, CV mortality may not be elevated 
during the early years of RA. Glucocorticoids 
were associated with increased CV mortality 
in early RA, whereas methotrexate was 
associated with decreased CV mortality. 
Mortality studies from the 2000s with longer 
follow-up and accounting for confounding 
by indication are warranted to reveal causal 
eff ects of RA medications on CV mortality 
and to determine CV death rates in longer-
standing RA.
16  Limitations of the study
Th e main limitations arise from defi ciencies 
in our register data—we were unable to 
characterize our study populations based on 
factors other than sex, age, RF status, and 
disease duration, nor have we additional data 
on their clinical characteristics. Th us, we 
were unable to account for many important 
confounders. 
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Th e RA cases were those individuals 
who had been diagnosed by a rheumatologist 
to have RA, who had been prescribed long-
term antirheumatic medication and had 
been granted the special reimbursement for 
antirheumatic medications. We have no data 
on their fulfi lling of any RA classifi cation 
criteria. In addition, it must be noted that 
although we evaluated the prevalence of 
comorbidities at RA diagnosis, or more 
exactly, at the date of the granting of special 
reimbursement for RA, this date may occur a 
variable period of time aft er clinical onset of 
the disease, since the traditional hallmarks of 
RA develop with time.334
We were likely to underestimate CV 
disease prevalence among both RA patients 
and the general population to some extent, 
because their milder forms do not necessarily 
entitle patients to special reimbursement 
of medications. Especially noteworthy is 
that a signifi cant portion of hypertensive 
patients were likely to fall through our net. 
Since patients with mild hypertension are 
not eligible for the reimbursement, selection 
bias might aff ect our results. Th eoretically, 
a possible overlap in medications for 
various CV diseases may enable a patient 
with two or more CV diseases to get their 
medication reimbursements with only one 
reimbursement diagnosis. However, any 
imperfect coverage of patients suff ering from 
CV disease is likely to concern RA patients 
and the general population equally. 
Smoking, NSAIDs, and obesity can 
interfere with the relation between CHD 
and RA or RF status. Unfortunately, we 
were unable to collect data on these. 
Smoking is traditionally associated with 
RF-positive RA114 and is therefore unlikely 
to contribute to increased CHD risk among 
the RF-negative subset. Another potential 
confounder is the use of NSAIDs for joint 
pain before RA diagnosis; all NSAIDs have 
somewhat unfavorable CV risk profi les.213 In 
Studies I and II, however, use of any other 
RA medication such as glucocorticoids 
induces no such bias since the patients get 
their prescriptions and start on antirheumatic 
medications synchronously with the 
certifi cate entitling to special reimbursement 
for those medications, this date being the end 
of the observation period.
Identifying RA patients with 
hypothyroidism based on special medicine 
reimbursements encompasses not only 
cases of autoimmune thyroiditis but 
also hypothyroidism arising from other 
etiologies. Chronic autoimmune thyroiditis, 
however, is the most common reason for 
acquired hypothyroidism,313 making most 
hypothyroid patients thus likely to represent 
an autoimmune etiology behind the 
condition. At least thyroid cancer is quite rare 
in Finland, as indicated by its mean annual 
incidence of 84 in men and 266 in women in 
2002-2006.335 Another important limitation is 
that coverage of clinical hypothyroidism may 
be relatively low because levothyroxine is so 
inexpensive that, in some cases, the patients 
may choose not to pay for the doctor’s 
certifi cate needed to apply for the special 
reimbursement. Obviously, this is equally 
true both of the general population and of 
those who will later develop RA; hence, it will 
not cause bias in assessment of relative risk 
for hypothyroidism. 
Absolute rates of disability pensions are 
diffi  cult to compare among countries because 
their social insurance systems vary widely, 
and diff erences exist in the process of sick 
listing. Th is makes generalizing our results to 
many other countries challenging. Further, 
in multimorbid patients, selecting the illness 
that restricts working ability the most may 
not be straightforward.
In examining CV mortality rates, we 
were unable to account for disease severity or 
degree of infl ammation. Th us, confounding 
by indication is most likely to have aff ected 
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our results for RA medications. One strength 
of the medication analyses was our being able 
to evaluate RA-medication use not only at 
baseline but during the entire follow-up.
A Finnish study on autopsy fi ndings 
from 1952-1991 indicated that RA patients 
were less accurately diagnosed with CV 
and coronary deaths than were non-RA 
patients by clinicians before autopsy, 
when compared with the causes of death 
suggested by pathologists aft er autopsy.336 
Th erefore, less accurate diagnosis of CV 
death among RA patients is a potential 
source of error when comparing their CV 
mortality rates with the general population’s. 
A methodological advantage to our mortality 
study was that we used, instead of normal 
survival analyses, competing-risks regression 
models and cumulative incidence functions, 
both better suited for situations in which 
competing events can preclude the event of 
interest.337 Competing causes of death such as 
malignancies may have, however, aff ected the 
point estimates of SMR for CV deaths. 
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Conclusions
1. Since comorbidities are relatively common in RA and have diverse eff ects on many 
crucial outcomes, preventing and targeting them should be an important aspect in 
the treatment of RA.
2. Th e prevalence of CHD was elevated among RA patients already at the time 
of diagnosis. Our fi ndings highlight the importance of CV risk detection and 
management as soon as RA is diagnosed, both in RF-positive and RF-negative 
patients.
3. Risk for hypothyroidism was already elevated at RA diagnosis, especially among 
the young women, regardless of RF status. Th is calls for attention to screening for 
hypothyroidism among RA patients, preferably even when RA is diagnosed.
4. Th e number of disability pensions resulting from psychiatric or CV comorbidities 
was minimal in comparison to the disability pensions for by RA itself. Compared 
to the general population, risk for WD due to CV disease was increased, but it was 
similar regarding psychiatric comorbidities.
5. During the era of modern RA treatment regimens, risk of CV death during the 
early years of RA was not increased. Th is risk may, however, increase in later stages 
of RA.
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